

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

These guidelines were developed by the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children convened by the National Pediatric and Family HIV Resource Center (NPHRC), the Health Resources and Services Administration (HRSA), and the National Institutes of Health (NIH). The Co-Chairs of the Working Group were James Oleske, M.D., M.P.H., University of Medicine and Dentistry of New Jersey (UMDNJ)-New Jersey Medical School, Newark, New Jersey, and Gwendolyn B. Scott, M.D., University of Miami School of Medicine, Miami, Florida.

Members of the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children who participated in the development of this document included:

Elaine Abrams, M.D. (Harlem Hospital Center, New York, NY); Arthur Ammann, M.D. (Global Strategies of HIV Prevention, San Rafael, CA); Martin Anderson, M.D., M.P.H. (University of California at Los Angeles, Los Angeles, CA); Carol Baker, M.D. (Baylor College of Medicine, Houston, TX); Lawrence Bernstein, M.D. (Albert Einstein College of Medicine, Bronx, NY); Michael Brady, M.D. (Columbus Children's Hospital, Columbus, OH); Kathleen Brooke (Family Representative); Sandra Burchett, M.D. (Children's Hospital, Boston, MA); Carolyn Burr, R.N, Ed.D. (NPHRC, Newark, NJ); Joseph Cervia, M.D. (Long Island Jewish Medical Center, New Hyde Park, NY); Diana Clarke, Pharm.D. (Boston Medical Center, Boston, MA); Daniel Collado (Family Representative); Ellen Cooper, M.D. (Boston University School of Medicine, Boston, MA); Marilyn Crain, M.D., M.P.H. (University of Alabama at Birmingham, Birmingham, AL); Barry Dashefsky, M.D. (NPHRC and UMDNJ-New Jersey Medical School, Newark, NJ); Carol DiPaolo (Family Representative); Diane Donovan (Family Representative); Janet A. Englund, M.D. (University of Chicago Hospitals, Chicago, IL); Mary Glenn Fowler, M.D., M.P.H. (Centers for Disease Control and Prevention, Atlanta, GA); Lisa M. Frenkel, M.D. (University of Washington, Seattle, WA); Donna Futterman, M.D. (Montefiore Medical Center, Bronx, NY); Anne Gershon, M.D. (Columbia University, New York, NY); Samuel Grubman, M.D. (St. Vincent's Hospital and Medical Center of New York, New York, NY); Peter Havens, M.D. (Children's Hospital of Wisconsin, Milwaukee, WI); Karen Hench, M.S., (HRSA, Rockville, MD); Neal Hoffman, M.D. (Montefiore Medical Center, Bronx, NY); Walter Hughes, M.D. (St. Jude Children's Research Hospital, Memphis, TN); Nancy Hutton, M.D. (Johns Hopkins School of Medicine, Baltimore, MD); George Johnson, M.D. (Medical University of South Carolina, Charleston, SC); Mark Kline, M.D. (Baylor College of Medicine, Houston, TX); Andrea Kovacs, M.D. (LAC + USC Medical Center, Los Angeles, CA); Keith Krasinski, M.D. (New York University School of Medicine, New York, NY); Linda Lewis, M.D. (FDA, Rockville, MD); Mary Lou Lindegren, M.D. (CDC, Atlanta, GA); Kathleen McGann, M.D. (Washington University School of Medicine, St. Louis, MO); Kenneth McIntosh, M.D. (Children's Hospital, Boston, MA); Ross McKinney, M.D. (Duke University Medical Center, Durham, NC); James McNamara, M.D. (NIH, Bethesda, MD); George McSherry, M.D. (UMDNJ-New Jersey Medical School, Newark, NJ); Mark Mintz,

M.D. (Bancroft NeuroHealth, Cherry Hill, NJ); Charles Mitchell, M.D. (University of Miami School of Medicine, Miami, FL); Lynne M. Mofenson, M.D. (NIH, Bethesda, MD); John Moye, Jr., M.D. (NIH, Bethesda, MD); Sharon Murphy, M.D. (Children's Memorial Hospital, Chicago, IL); Sharon Nachman, M.D. (State University of New York Health Science Center at Stony Brook, Stony Brook, NY); Mary Jo O'Hara, R.N., M.S.N., C.P.N.P. (Northwest Family Center, Seattle, WA); James Oleske, M.D., M.P.H. (UMDNJ-New Jersey Medical School, Newark, NJ); Savita Pahwa, M.D. (North Shore University Hospital, Manhasset, NY); Paul Palumbo, M.D. (UMDNJ-New Jersey Medical School, Newark, NJ); Ligia Peralta, M.D. (University of Maryland, Baltimore, MD); Jane Pitt, M.D. (Columbia University Medical Center, New York, NY); Philip Pizzo, M.D. (Harvard Medical School/Children's Hospital, Boston, MA); Tamara Rakusan, M.D., Ph.D. (Children's Hospital, Washington, DC); Rosemary Ramroop (Family Representative); Lt. Merlin Robb, M.D. (Walter Reed Army Institute of Research, Rockville, MD); John Rodman, Pharm.D. (St. Jude Children's Research Hospital, Memphis, TN); Arye Rubinstein, M.D. (Albert Einstein College of Medicine, Bronx, NY); Gwendolyn Scott, M.D. (University of Miami School of Medicine, Miami, FL); Leslie Serchuck, M.D. (NIH, Bethesda, MD); John Sever, M.D., Ph.D. (Children's National Medical Center, Washington, DC); Minora Sharpe (Family Representative); William Shearer, M.D., Ph.D. (Baylor College of Medicine, Houston, TX); R.J. Simonds, M.D. (Centers for Disease Control and Prevention, Atlanta, GA); Peter Smith, M.D. (Hasbro Children's Hospital, Providence, RI); Stephen Spector, M.D. (University of California at San Diego, La Jolla, CA); Deborah Storm, Ph.D. (UMDNJ-New Jersey Medical School, Newark, NJ); Russell Van Dyke, M.D. (Tulane University School of Medicine, New Orleans, LA); Diane Wara, M.D. (University of California at San Francisco School of Medicine, San Francisco, CA); Catherine Wilfert, M.D. (Duke University Medical Center, Durham, NC; The Pediatric AIDS Foundation, Santa Monica, CA); Harland Winter, M.D. (Massachusetts General Hospital, Boston, MA); Andrew Wiznia, M.D. (Jacobi Medical Center, Bronx, NY); Ram Yogev (Children's Memorial Hospital, Chicago, IL).

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Summary

Although the pathogenesis of human immunodeficiency virus (HIV) infection and the general virologic and immunologic principles underlying the use of antiretroviral therapy are similar for all HIV-infected persons, there are unique considerations needed for HIV-infected infants, children, and adolescents, including a) acquisition of infection through perinatal exposure for many infected children; b) in utero exposure to ZDV and other antiretroviral medications in many perinatally infected children; c) differences in diagnostic evaluation in perinatal infection; d) differences in immunologic markers (i.e., CD4⁺ T cell count) in young children; e) changes in pharmacokinetic parameters with age caused by the continuing development and maturation of organ systems involved in drug metabolism and clearance; f) differences in the clinical and virologic manifestations of perinatal HIV infection secondary to the occurrence of primary infection in growing, immunologically immature persons; and g) special considerations associated with adherence to treatment for children and adolescents.

This report addresses the pediatric-specific issues associated with antiretroviral treatment and provides guidelines to health-care providers caring for infected infants, children, and adolescents. It is recognized that guidelines for antiretroviral use in pediatric patients are rapidly evolving. The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children will review new data on an ongoing basis and provide regular updates to the guidelines; the most recent information is available on the HIV/AIDS Treatment Information Service Website (<http://www.hivatis.org>).*

INTRODUCTION

In 1993, the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, composed of specialists caring for human immunodeficiency virus (HIV)-infected infants, children, and adolescents, was convened by the National Pediatric and Family HIV Resource Center (NPHRC). On the basis of available data and a consensus reflecting clinical experience, the Working Group concluded that antiretroviral therapy was indicated for any child with a definitive diagnosis of HIV infection who had evidence of substantial immunodeficiency (based on age-related CD4⁺ T cell count thresholds) and/or who had HIV-associated symptoms. ZDV monotherapy was recommended as the standard of care for initiation of therapy. Routine antiretroviral therapy for infected children who were asymptomatic or had only minimal symptoms (i.e., isolated lymphadenopathy or hepatomegaly) and normal immune status was not recommended (1).

Since the Working Group developed the 1993 recommendations, dramatic advances in laboratory and clinical research have been made. The rapidity and magnitude of HIV replication during all stages of infection are greater than previously believed and account for the emergence

* Information included in these guidelines may not represent Food and Drug Administration (FDA) approval or approved labeling for the particular product or indications in question. Specifically, the terms “safe” and “effective” may not be synonymous with the FDA-defined legal standards for product approval.

of drug-resistant viral variants when antiretroviral treatment does not maximally suppress replication (2, 3). New assays that quantitate plasma HIV RNA copy number have become available, permitting a sensitive assessment of risk for disease progression and adequacy of antiretroviral therapy. A new class of antiretroviral drugs, protease inhibitors, has become available; these agents have reduced HIV viral load to levels that are undetectable and have reduced disease progression and mortality in many HIV-infected persons. Therefore, therapeutic strategies now focus on early institution of antiretroviral regimens capable of maximally suppressing viral replication to reduce the development of resistance and to preserve immunologic function. Additionally, the results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 076 have demonstrated that the risk for perinatal HIV transmission can be substantially diminished with the use of a regimen of ZDV administered during pregnancy, during labor, and to the newborn (4).

These advances in HIV research have led to major changes in the treatment and monitoring of HIV infection in the United States. A summary of the basic principles underlying therapy of HIV-infected persons has been formulated by the National Institutes of Health (NIH) Panel to Define Principles of Therapy of HIV Infection (5). Treatment recommendations for infected adults and post-pubertal adolescents have been updated by the U.S. Department of Health and Human Services Panel of Clinical Practices for Treatment of HIV Infection (5). This document is regularly updated to reflect the most recent literature. The most recent update is available at www.hivatis.org.

Although the pathogenesis of HIV infection and the general virologic and immunologic principles underlying the use of antiretroviral therapy are similar for all HIV-infected persons, there are unique considerations needed for HIV-infected infants, children, and adolescents. Most HIV infections in children are acquired perinatally, and most perinatal transmission occurs during or near the time of birth, which raises the possibility of initiating treatment in an infected infant during the period of initial (i.e., primary) HIV infection (if sensitive diagnostic tests are used to define the infant's infection status early in life). Perinatal HIV infection occurs during the development of the infant's immune system; thus, both the clinical manifestations of HIV infection and the course of immunologic and virologic markers of infection differ from those for adults. Treatment of perinatally infected children will occur in the context of prior exposure to ZDV and other antiretroviral drugs used during pregnancy and the neonatal period, for maternal treatment, to prevent perinatal transmission, or both (6, 7). Additionally, drug pharmacokinetics change during the transition from the newborn period to adulthood, requiring specific evaluation of drug dosing and toxicity in infants and children. Finally, optimizing adherence to therapy in children and adolescents requires specific considerations.

To update the 1993 antiretroviral treatment guidelines for children (1) and to provide guidelines for antiretroviral treatment similar to those for HIV-infected adults (5), NPHRC, the Health Resources and Services Administration (HRSA), and NIH reconvened the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, consisting of experts caring for HIV-infected children and adolescents, family members of HIV-infected children, and government agency representatives. The Working Group met in June 1996 and again in July 1997 to establish and finalize new guidelines for the treatment of HIV-infected infants, children, and adolescents. These were initially published in 1998 both in MMWR (8) which is periodically updated and as a supplement to the journal *Pediatrics*. (9) The supplement

included both antiretroviral therapy as well as management of complications of HIV infection. This material will be accessible by a hyperlink from this document in the near future.

The treatment recommendations provided in this updated report are based on published and unpublished data regarding the treatment of HIV infection in adults and children and, when no definitive data were available, the clinical experience of the Working Group members. The Working Group intended the guidelines to be flexible and not to supplant the clinical judgment of experienced health-care providers. These guidelines will be modified by the Working Group as new information and clinical experience become available. The most recent information is available on the HIV/AIDS Treatment Information Service Website (<http://www.hivatis.org>).

BACKGROUND

Concepts Considered in the Formulation of Pediatric Treatment Guidelines

The following concepts were considered in the formulation of these guidelines:

- Identification of HIV-infected women before or during pregnancy is critical to providing optimal therapy for both infected women and their children and to preventing perinatal transmission. Therefore, prenatal HIV counseling and testing with consent should be the standard of care for all pregnant women in the United States (10-12).
- Enrollment of pregnant HIV-infected women; their HIV-exposed newborns; and infected infants, children, and adolescents into clinical trials offers the best means of determining safe and effective therapies.*
- Pharmaceutical companies and the federal government should collaborate to ensure that drug formulations suitable for administration to infants and children are available at the time that new agents are being evaluated in adults.
- Although some information regarding the efficacy of antiretroviral drugs for children can be extrapolated from clinical trials involving adults, concurrent clinical trials for children are needed to determine the impact of the drug on specific manifestations of HIV infection in children, including growth, development, and neurologic disease. However, the absence of clinical trials addressing pediatric-specific manifestations of HIV infection does not preclude the use of any approved antiretroviral drug in children.
- All antiretroviral drugs approved for treatment of HIV infection may be used for children when indicated — irrespective of labeling notations.
- Management of HIV infection in infants, children, and adolescents is rapidly evolving and becoming increasingly complex; therefore, wherever possible, management of HIV infection in children and adolescents should be directed by a specialist in the treatment of pediatric and adolescent HIV infection. If this is not possible, such experts should be consulted regularly.

* In areas where enrollment in clinical trials is possible, enrolling the child in available trials should be discussed with the caregivers of the child. Information about clinical trials for HIV-infected adults and children can be obtained from the AIDS Clinical Trials Information Service, telephone (800) 874-2572 ([800] TRIALS-A), or their Website (<http://www.actis.org>).

- Effective management of the complex and diverse needs of HIV-infected infants, children, adolescents, and their families requires a multidisciplinary team approach that includes physicians, nurses, social workers, psychologists, nutritionists, outreach workers, and pharmacists.
- Determination of HIV RNA copy number and CD4⁺ T cell levels is essential for monitoring and modifying antiretroviral treatment in infected children and adolescents as well as adults; therefore, assays to measure these variables should be made available.
- Health-care providers considering antiretroviral regimens for children and adolescents should consider certain factors influencing adherence to therapy, including a) availability and palatability of pediatric formulations; b) impact of the medication schedule on quality of life, including number of medications, frequency of administration, ability to coadminister with other prescribed medications, and need to take with or without food; c) ability of the child's caregiver or the adolescent to administer complex drug regimens and availability of resources that might be effective in facilitating adherence; and d) potential for drug interactions.
- The choice of antiretroviral regimens should include consideration of factors associated with possible limitation of future treatment options, including the presence of or potential for the development of antiretroviral resistance. HIV resistance assays may prove useful in guiding initial therapy and in changing failing regimens but their value in children has not been established and expert clinical interpretation is required. These assays should be made available for perinatally infected children.
- Monitoring growth and development is essential for the care of HIV-infected children. Growth failure and neurodevelopmental deterioration may be specific manifestations of HIV infection in children. Nutritional-support therapy is an intervention that affects immune function, quality of life, and bioactivity of antiretroviral drugs.

Identification of Perinatal HIV Exposure

Appropriate treatment of HIV-infected infants requires HIV-exposed infants to be identified as soon as possible, which can be best accomplished through the identification of HIV-infected women before or during pregnancy. Universal HIV counseling and voluntary HIV testing with consent are recommended as the standard of care for all pregnant women in the United States by the Public Health Service (PHS), the American Academy of Pediatrics, and the American College of Obstetricians and Gynecologists and are endorsed by the Working Group (10-12).

Early identification of HIV-infected women is crucial for the health of such women and for care of HIV-exposed and HIV-infected children. Knowledge of maternal HIV infection during the antenatal period enables: a) HIV-infected women to receive appropriate antiretroviral therapy and prophylaxis against opportunistic infections for their own health; b) provision of antiretroviral chemoprophylaxis with ZDV during pregnancy, during labor, and to newborns to reduce the risk for HIV transmission from mother to child (4, 6, 13); c) counseling of infected women about the risks for HIV transmission through breast milk and advising against breast feeding in the United States and other countries where safe alternatives to breast milk are available (14); d) initiation of prophylaxis against *Pneumocystis carinii* pneumonia (PCP) in all HIV-exposed infants beginning at age four to six weeks in accordance with PHS guidelines (15);

and e) early diagnostic evaluation of HIV-exposed infants to permit early initiation of aggressive antiretroviral therapy in infected infants.

If women are not tested for HIV during pregnancy, counseling and HIV testing should be recommended during the immediate postnatal period. **When maternal serostatus has not been determined during the prenatal or immediate postpartum period, newborns should undergo HIV antibody testing with counseling and consent of the mother unless state law allows testing without consent (16).** The HIV-exposure status of infants should be determined rapidly because the neonatal component of the recommended ZDV chemoprophylaxis regimen should begin as soon as possible after birth and because PCP prophylaxis should be initiated at age four to six weeks in all infants born to HIV-infected women. Those infants who have been abandoned, are in the custody of the state, or have positive toxicology screening tests should be considered at high risk for exposure to HIV, and mechanisms to facilitate rapid HIV screening of such infants should be developed.

Diagnosis of HIV Infection in Infants

HIV infection can be definitively diagnosed in most infected infants by age one month and in virtually all infected infants by age six months by using viral diagnostic assays. A positive virologic test (i.e., detection of HIV by culture or DNA or RNA polymerase chain reaction [PCR]) indicates possible HIV infection and should be confirmed by a repeat virologic test on a second specimen as soon as possible after the results of the first test become available.

Diagnostic testing should be performed before the infant is age 48 hours, at age one to two months, and at age three to six months. Testing at age 14 days also may be advantageous for early detection of infection. HIV-exposed infants should be evaluated by or in consultation with a specialist in HIV infection in pediatric patients.

HIV DNA PCR is the preferred virologic method for diagnosing HIV infection during infancy. A meta-analysis of published data from 271 infected children indicated that HIV DNA PCR was sensitive for the diagnosis of HIV infection during the neonatal period. Thirty-eight percent (90% confidence interval [CI] = 29%-46%) of infected children had positive PCR tests by age 48 hours (17). No substantial change in sensitivity during the first week of life was observed, but sensitivity increased rapidly during the second week, with 93% of infected children (90% CI = 76%-97%) testing positive by PCR by age 14 days.

Assays that detect HIV RNA in plasma also may be useful for diagnosis of perinatal infection and may prove to be more sensitive than DNA PCR for early diagnosis of HIV infection in HIV-exposed infants (18). However, data are more limited regarding the sensitivity and specificity of HIV RNA assays compared with HIV DNA PCR for early diagnosis.

HIV culture has a sensitivity similar to that of DNA PCR for the diagnosis of infection (19). However, HIV culture is more complex and expensive to perform than DNA PCR, and definitive results may not be available for two to four weeks. Although use of standard and immune-complex-dissociated p24 antigen tests are highly specific for HIV infection and have been used to diagnose infection in children, the sensitivity of these tests is less than the sensitivity of other HIV virologic tests. The use of p24 antigen testing alone is not recommended to exclude infection or for diagnosis of infection in infants aged less than a month because of a high frequency of false-positive assays during this time (20).

Initial testing is recommended by age 48 hours because nearly 40% of infected infants can be identified at this time. Because of concerns regarding potential contamination with maternal blood, blood samples from the umbilical cord should not be used for diagnostic evaluations. Working definitions have been proposed for acquisition of HIV infection during the intrauterine and intrapartum periods. Infants who have a positive virologic test at or before age 48 hours are considered to have early (i.e., intrauterine) infection, whereas infants who have negative a virologic test during the first week of life and subsequent positive tests are considered to have late (i.e., intrapartum) infection (21). Some researchers have proposed that infants with early infection may have more rapid disease progression than those with late infection and therefore should receive a more aggressive therapeutic approach (21, 22). However, recent data from prospective cohort studies have demonstrated that although early differences in HIV RNA levels have been present between infants with positive HIV culture within 48 hours of birth and those with a first positive culture after age seven days, these differences were no longer statistically significant after age two months (23). HIV RNA copy number after the first month of life was more prognostic of rapid disease progression than the time at which HIV culture tests were positive (23). Repeat diagnostic testing also can be considered at age 14 days in infants with negative tests at birth, because the diagnostic sensitivity of virologic assays increases rapidly by age two weeks and early identification of infection would permit modification of antiretroviral therapy from the standard six-week course of neonatal ZDV chemoprophylaxis to more aggressive combination antiretroviral therapy.

Infants with initially negative virologic tests should be re-tested at age one to two months. With increasing use of ZDV to reduce perinatal transmission, most HIV-exposed neonates will receive six weeks of antiretroviral chemoprophylaxis. Although prophylactic antiretroviral therapy theoretically could affect the predictive value of HIV virologic testing in neonates, ZDV monotherapy did not delay the detection of HIV by culture in infants in PACTG protocol 076 and has not decreased the sensitivity and predictive values of many virologic assays (4, 24). However, whether the current, more intensive combination antiretroviral regimens women may receive during pregnancy for treatment of their own HIV infection will affect diagnostic test sensitivity in their infants is unknown.

HIV-exposed children who have had repeatedly negative virologic assays at birth and at age one to two months should be retested again at age three to six months. HIV infection is diagnosed by two positive HIV virologic tests performed on separate blood samples. HIV infection can be reasonably excluded among children with two or more negative virologic tests, two of which are performed at age ≥ 1 month, and one of those being performed at age ≥ 4 months (15). Two or more negative HIV immunoglobulin G (IgG) antibody tests performed at age >6 months with an interval of at least one month between the tests also can be used to reasonably exclude HIV infection among children with no clinical evidence of HIV infection. HIV infection can be definitively excluded if HIV IgG antibody is negative in the absence of hypogammaglobulinemia at age 18 months and if the child has both no clinical symptoms of HIV infection and negative HIV virologic assays.

Monitoring of Pediatric HIV Infection

Immunologic Parameters in Children

Clinicians interpreting CD4⁺ T cell count for children must consider age as a variable. CD4⁺ T cell count and percentage values in healthy infants who are not infected with HIV are considerably higher than those observed in uninfected adults and slowly decline to adult values by age six years (25, 26). A pediatric clinical and immunologic staging system for HIV infection has been developed that includes age-related definitions of immune suppression ([Table 1](#) and [Table 2](#)) (27). Although the CD4⁺ T cell absolute count that identifies a specific level of immune suppression changes with age, the CD4⁺ T cell percentage that defines each immunologic category does not. Thus, a change in CD4⁺ percentage, not number, may be a better marker of identifying disease progression in children. In infected children and adults, the CD4⁺ T cell count declines as HIV infection progresses, and patients with lower CD4⁺ T cell counts have a poorer prognosis than patients with higher counts ([Table 3](#)).

Because knowledge of immune status (i.e., CD4⁺ T cell count and percentage) is essential when caring for HIV-infected infants and children, CD4⁺ T cell values should be obtained as soon as possible after a child has a positive virologic test for HIV and every three months thereafter (28, 29). Infected infants who have a thymic defect lymphocyte immunophenotypic profile (i.e., CD4⁺ T cell count <1,900/mm³ and CD8⁺ T cell count >850/mm³) during the first six months of life have had more rapid HIV disease progression than infants who do not have this profile (30).

The CD4⁺ T cell count or percentage value is used in conjunction with other measurements to guide antiretroviral treatment decisions and primary prophylaxis for PCP after age one year. However, measurement of CD4⁺ T cell values can be associated with considerable inpatient variation. Even mild intercurrent illness or the receipt of vaccinations can produce a transient decrease in CD4⁺ T cell count and percentage; thus, CD4⁺ T cell values are best measured when patients are clinically stable. No modification in therapy should be made in response to a change in CD4⁺ T cell values until the change has been substantiated by at least a second determination, with a minimum of one week between measurements.

HIV RNA in Children

Viral burden in peripheral blood can be determined by using quantitative HIV RNA assays. During the period of primary infection in adults, HIV RNA copy number initially rises to high peak levels. Coincident with the body's humoral and cell-mediated immune response, RNA levels decline by as much as 2-3 log₁₀ copies to reach a stable lower level (i.e., the virologic set-point) approximately six to twelve months following acute infection, reflecting the balance between ongoing viral production and immune elimination (31, 32). Several studies conducted among adults have indicated that infected persons with lower HIV copy number at the time of RNA stabilization have slower progression and improved survival compared with those with high HIV RNA set points (33, 34). On the basis of such data, recommendations for the use of HIV RNA copy number in deciding to initiate and change antiretroviral therapy in infected adults have been developed (5). These recommendations also are applicable to infected adolescents, particularly those who have acquired HIV infection recently rather than through perinatal infection. These recommendations also are likely to be applicable to perinatally infected children aged >3 years.

The HIV RNA pattern in perinatally infected infants differs from that in infected adults. High HIV RNA copy numbers persist in infected children for prolonged periods (35, 36). In one prospective study, HIV RNA levels generally were low at birth (i.e., <10,000 copies/mL), increased to high values by age two months (most infants had values >100,000 copies/mL, ranging from undetectable to nearly 10 million copies/mL), and then decreased slowly; the mean HIV RNA level during the first year of life was 185,000 copies/mL (23). Additionally, in contrast to the adult pattern, after the first year of life, HIV RNA copy number slowly declines over the next few years of life (23, 37-39). This pattern probably reflects the lower efficiency of an immature but developing immune system in containing viral replication and possibly a greater number of HIV-susceptible cells.

Recent data indicate that high HIV RNA levels (i.e., >299,000 copies/mL) in infants aged <12 months may be correlated with disease progression and death; however, RNA levels in infants who have rapid disease progression and those who do not have overlapped considerably (23, 36). High RNA levels (i.e., levels of >100,000 copies/mL) in infants also have been associated with high risk for disease progression and mortality, particularly if CD4⁺ T cell percentage is <15% (Table 4 and Table 5) (38). Similar findings have been reported in a preliminary analysis of data from PACTG protocol 152 correlating baseline virologic data with risk for disease progression or death during study follow-up (Table 6) (39). In this study, the relative risk for disease progression was reduced by 54% for each 1 log₁₀ decrease in baseline HIV RNA level. Disease progression was documented in 11% of children aged <30 months at the time the study was initiated (mean age: 1.1 years) who had baseline RNA in the lowest quartile (i.e., from undetectable to 150,000 copies/mL) and in 52% of children with baseline RNA in the highest quartile (i.e., >1,700,000 copies/mL) (39). Among children aged ≥30 months at the time the study was initiated (mean age: 7.3 years), none of those with baseline RNA in the lowest quartile (i.e., undetectable to 15,000 copies/mL) compared with 34% of those in the highest quartile (i.e., >150,000 copies/mL) had disease progression; children with RNA levels in the middle two quartiles (i.e., 15,000-50,000 and 50,001-150,000 copies/mL) had similar progression rates (13% and 16%, respectively). Data from children aged ≥30 months are similar to data from studies among infected adults, in which the risk for disease progression substantially increases when HIV RNA levels exceed 10,000-20,000 copies/mL (5).

Despite data indicating that high RNA levels are associated with disease progression, the predictive value of specific HIV RNA levels for disease progression and death for an individual child is moderate (38). HIV RNA levels may be difficult to interpret during the first year of life because levels are high and there is marked overlap in levels between children who have and those who do not have rapid disease progression (35). Additional data indicate that CD4⁺ T cell percentage and HIV RNA copy number at baseline and changes in these parameters over time assist in determining the mortality risk in infected children, and the use of the two markers together may more accurately define prognosis (38, 39). Similar data and conclusions recently have been reported from several studies involving infected adults (40-42).

Methodologic Considerations in the Interpretation and Comparability of HIV RNA Assays

Most of the published data regarding HIV RNA in children have been obtained using frozen, stored plasma and serum specimens. Some degradation of HIV RNA occurs with specimen storage and delay in specimen processing; thus, the published data on HIV RNA levels in

infected children may not be directly comparable with data obtained from specimens that undergo immediate testing (i.e., specimens obtained for patient care). The HIV RNA assays used also differ by study. Therefore, direct extrapolation of the predictive value of HIV RNA levels reported in published studies to HIV RNA assays performed for clinical-care purposes may be problematic. Information from ongoing prospective studies will assist in the interpretation of HIV RNA levels among infected infants and children.

The use of HIV RNA assays for clinical purposes requires specific considerations (43), which are discussed more completely elsewhere (5). Several different methods can be used for quantitating HIV RNA, each with different levels of sensitivity. Although the results of the assays are correlated, the absolute HIV RNA copy number obtained from a single specimen tested by two different assays can differ by twofold ($0.3 \log_{10}$) or more. For example, plasma RNA measured by the quantitative PCR assay (Amplicor HIV-1 Monitor™, manufactured by Roche Diagnostics Systems, Nutley, New Jersey) yields absolute values approximately twice ($0.3 \log_{10}$) those obtained using a signal amplification, branched-chain DNA assay (Quantiplex®, manufactured by Chiron Corporation, Emeryville, California) (5, 44, 45). Similarly, plasma RNA measured by the nucleic acid sequence-based amplification assay (NASBA®, manufactured by Organon Teknika, Durham, North Carolina) yields absolute values approximately twice those obtained using the Quantiplex® assay but values relatively comparable with those obtained using the Amplicor HIV-1 Monitor™ assay (44-46). Therefore, one HIV RNA assay method should be used consistently for monitoring each patient. Choice of HIV RNA assay, particularly for young children, may be influenced by the amount of blood required for the assay. The NASBA® assay requires the least amount of blood (i.e., 100 μ L of plasma), followed by the Amplicor HIV-1 Monitor™ (i.e., 200 μ L of plasma) and the Quantiplex® assays (i.e., 1 mL of plasma).

Biologic variation in HIV RNA levels within one person is well documented, and repeated measurement of HIV RNA levels in a clinically stable infected adult can vary by as much as threefold ($0.5 \log_{10}$) in either direction over the course of a day or on different days (5, 42, 47). This biologic variation may be greater in infected infants and young children. In children with perinatally acquired HIV infection, RNA copy number slowly declines even without therapy during the first several years after birth, although it persists at higher levels than those observed in most infected adults (23, 37, 38). This decline is most rapid during the first 12-24 months after birth, with an average decline of approximately $0.6 \log_{10}$ per year; a slower decline continues until approximately age four to five years (average decline of $0.3 \log_{10}$ per year). This inherent biologic variability must be considered when interpreting changes in RNA copy number in children. Thus, only changes greater than fivefold ($0.7 \log_{10}$) in infants aged <2 years and greater than threefold ($0.5 \log_{10}$) in children aged ≥ 2 years after repeated testing should be considered reflective of a biologically and clinically substantial change. To reduce the impact of assay variability in the clinical management of patients, two samples can be obtained at baseline and the average of the two values used for comparison with future tests. No alteration in therapy should be made as a result of a change in HIV copy number unless the change is confirmed by a second measurement. Because of the complexities of HIV RNA testing and the age-related changes in HIV RNA in children, interpretation of HIV RNA levels for clinical decision-making should be done by or in consultation with an expert in pediatric HIV infection.

Specific Issues in Antiretroviral Therapy for HIV-Infected Adolescents

Adult guidelines for antiretroviral therapy are appropriate for postpubertal adolescents because HIV-infected adolescents who were infected sexually or through injecting-drug use during adolescence follow a clinical course that is more similar to that of adults than to that of children (5). The immunopathogenesis and virologic course of HIV infection in adolescents is being defined. Most adolescents have been infected during their teenage years and are in an early stage of infection, making them ideal candidates for early intervention. A limited but increasing number of HIV-infected adolescents are long-term survivors of HIV infection acquired perinatally or through blood products as young children. Such adolescents may have a unique clinical course that differs from that of adolescents infected later in life (48). Because many adolescents with HIV infection are sexually active, issues associated with contraception and prevention of HIV transmission should be discussed between the health-care provider and the adolescent.

Dosage for medications for HIV infection and opportunistic infections should be prescribed according to Tanner staging of puberty (49) and not on the basis of age (28). Adolescents in early puberty (i.e., Tanner Stage I and II) should be administered doses using pediatric schedules, whereas those in late puberty (i.e., Tanner Stage V) should follow adult dosing schedules. Youth who are in their growth spurt (i.e., Tanner Stage III in females and Tanner Stage IV in males) should be closely monitored for medication efficacy and toxicity when using adult or pediatric dosing guidelines.

Puberty is a time of somatic growth and sex differentiation, with females developing more body fat and males more muscle mass. Although these physiologic changes theoretically could affect drug pharmacokinetics (especially for drugs with a narrow therapeutic index that are used in combination with protein-bound medicines or hepatic enzyme inducers or inhibitors), no clinically consequential impact has been noted with nucleoside analogue reverse transcriptase inhibitor (NRTI) antiretroviral drugs (50). Clinical experience with PIs and non-nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral drugs is more limited.

Specific Issues of Adherence for HIV-Infected Children and Adolescents

Lack of adherence to prescribed regimens and subtherapeutic levels of antiretroviral medications may enhance the development of drug resistance. Data indicate that the development of resistance to one of the available PI antiretrovirals may reduce susceptibility to some or all of the other available PI drugs, thus substantially reducing subsequent treatment options. Similarly, the development of resistance to one of the available NNRTIs may be associated with resistance to the other members of the NNRTI class of drugs. Therefore, education of infected children and/or their caregivers regarding the importance of compliance with the prescribed drug regimen is necessary when therapy is initiated and should be reinforced during subsequent visits. Many strategies can be used to increase medication adherence, including intensive patient education over several visits before therapy is initiated, the use of cues and reminders for administering drugs, development of patient-focused treatment plans to accommodate specific patient needs, and mobilization of social and community support services.

Adherence to drug regimens is especially problematic for children. Infants and young children are dependent on others for administration of medication; thus, assessment of the capacity for adherence to a complex multidrug regimen requires evaluation of the caregivers and their

environments and the ability and willingness of the child to take the drug. Liquid formulations or formulations suitable for mixing with formula or food are necessary for administration of oral drugs to young children. Lack of palatability of such formulations can be problematic depending on the child's willingness and ability to accept and retain the medication. Absorption of some antiretroviral drugs can be affected by food, and attempting to time the administration of drugs around meals can be difficult for caregivers of young infants who require frequent feedings. Many other barriers to adherence to drug regimens exist for children and adolescents with HIV infection. For example, unwillingness of the caregivers to disclose their child's HIV infection status to others may create specific problems, including reluctance of caregivers to fill prescriptions in their home neighborhood, hiding or relabeling medications to maintain secrecy within the home, reduction of social support (a variable associated with diminished treatment adherence), and a tendency to eliminate midday doses when the parent is away from the home or the child is at school.

A comprehensive assessment of adherence issues should be instituted for all children in whom antiretroviral treatment is considered; evaluations should include nursing, social, and behavioral assessments. Intensive follow-up is required particularly during the critical first few months after therapy is started; patients should be seen frequently to assess adherence, drug tolerance, and virologic response. Coordinated, comprehensive, family-centered systems of care often can address many of the daily problems facing families that may affect adherence to complex medical regimens. For some families, certain issues (i.e., a safe physical environment and adequate food and housing) may take priority over medication administration and need to be resolved. Case managers, mental-health counselors, peer educators, outreach workers, and other members of the multidisciplinary team often may be able to address specific barriers to adherence.

HIV-infected adolescents have specific adherence problems. Comprehensive systems of care are required to serve both the medical and psychosocial needs of HIV-infected adolescents, who are frequently inexperienced with health-care systems. Many HIV-infected adolescents face challenges in adhering to medical regimens for reasons that include a) denial and fear of their HIV infection; b) misinformation; c) distrust of the medical establishment; d) fear and lack of belief in the effectiveness of medications; e) low self-esteem; f) unstructured and chaotic lifestyles; and g) lack of familial and social support. Treatment regimens for adolescents must balance the goal of prescribing a maximally potent antiretroviral regimen with realistic assessment of existing and potential support systems to facilitate adherence.

Developmental issues make caring for adolescents unique. The adolescent's approach to illness is often different from that of an adult. The concrete thought processes of adolescents make it difficult for them to take medications when they are asymptomatic, particularly if the medications have side effects. Adherence with complex regimens is particularly challenging at a time of life when adolescents do not want to be different from their peers. Further difficulties face adolescents who live with parents to whom they have not yet disclosed their HIV status and those who are homeless and have no place to store medicine.

TREATMENT RECOMMENDATIONS

General Considerations

Issues associated with adherence to treatment are especially important in considering whether and when to initiate therapy. Antiretroviral therapy is likely to be most effective in patients who are naive to treatment and who therefore are less likely to have antiretroviral-resistant viral strains. Lack of adherence to prescribed regimens and subtherapeutic levels of antiretroviral medications, particularly protease inhibitors, may enhance the development of drug resistance and likelihood of virologic failure (51, 52). Participation by the caregivers and child in the decision-making process is crucial, especially in situations for which definitive data concerning efficacy are not available.

HIV-Infected Children with Immunologic or Clinical Symptoms of Infection

Antiretroviral therapy has provided substantial clinical benefit to HIV-infected children with immunologic or clinical symptoms of HIV infection, particularly as more potent therapies have become available. Initial clinical trials of monotherapy with ZDV, didanosine (ddI), lamivudine (3TC), or stavudine (d4T) demonstrated substantial improvements in neurodevelopment, growth, and immunologic and/or virologic status (53-58). Subsequent pediatric clinical trials in symptomatic, antiretroviral-naïve children have demonstrated that combination therapy with either ZDV and 3TC or ZDV and ddI is clinically, immunologically, and virologically superior to monotherapy with ddI or ZDV as initial therapy (35, 59). In clinical trials in antiretroviral-experienced children, combination therapy that included a protease inhibitor was shown to be virologically and immunologically superior to dual nucleoside combination therapy (60).

The recognition of the enhanced potency of combination therapy and the identification of new viral targets and classes of antiretroviral agents has led to improvements in antiretroviral therapy that have been accompanied by enhanced survival of HIV-infected children and a reduction in opportunistic infections and other complications of HIV infection. This was demonstrated in a prospective longitudinal cohort study, PACTG 219 that started enrollment prior to the availability of protease inhibitor therapy. The increased use of protease inhibitor-containing highly active combination therapy (from 0% prior to 1996 to over 70% by 1998) was accompanied by a substantial decrease in mortality: mortality was only 1% in 1997/1998 compared to 5% in 1995/1996 (61). A similar reduction in mortality with introduction of combination therapy in HIV-infected children in Italy has also been reported (62).

Asymptomatic HIV-Infected Children

When to initiate therapy for asymptomatic infants and older children with normal immune function is less certain. Phase III clinical trial data to address the effectiveness of antiretroviral therapy in this group are not available. However, it is known that control of viral replication is particularly poor in perinatally infected infants, as demonstrated by the high levels of HIV RNA that are observed during the first 1-2 years of life following perinatal infection. Initiation of aggressive antiretroviral therapy during this early period of viral replication could theoretically preserve immune function, diminish viral dissemination, lower the steady state viral load, and result in improved clinical outcome. Preliminary data from clinical trials of early antiretroviral therapy with three- and four-drug combinations in antiretroviral-naïve HIV-infected children

under two years of age (some as young as 15 days) indicate that initiation of therapy early in the course of HIV infection, including during the period of primary infection in the neonate, may be able to produce long-term suppression of viral replication and preservation of immune function in some children (63, 64). However, the proportion of children who achieve HIV RNA levels below the limits of detection with potent therapy may be lower among young infants than older children and adults, in part because virologic response is related to viral load at the time therapy is initiated (60, 65) and young infants have substantially higher viral loads (23). Although a complete virologic response may not be attained in all children, some studies have suggested that immunologic and clinical benefit may be observed in individuals who are partial responders to therapy (66, 67).

The potential problems with early therapy include the risk of short- and long-term adverse effects, particularly for drugs given to very young infants, where there are only limited data on pharmacokinetics, drug dosing, and safety. These concerns are particularly relevant because life-long administration of therapy may be necessary, and studies in both adults and children have suggested that optimal benefit may be achieved with the first regimen. Additionally, if viral replication is not suppressed, ongoing viral mutation is likely to result in the development of antiretroviral resistance, curtailing the duration of benefit that early therapy might confer and potentially limiting future treatment options.

When to Initiate Therapy ([Table 7](#))

Before antiretroviral therapy is initiated, it is critical that caregivers and patients (when age-appropriate) are counseled regarding the importance of adherence to the prescribed treatment regimen. Potential problems should be identified and resolved prior to starting therapy, even if this delays initiation of therapy. Additionally, frequent follow-up is important to provide assessment of virologic response to therapy, drug intolerance, viral resistance, and adherence.

HIV-Infected Children with Immunologic or Clinical Symptoms of Infection

Antiretroviral therapy is recommended for all HIV-infected children with clinical symptoms of HIV infection (i.e., those in clinical categories A, B, or C) ([Table 2](#)) or evidence of immune suppression (i.e., those in immune categories 2 or 3) ([Table 1](#)) — regardless of the age of the child or viral load ([Table 7](#)). Clinical trial data from both adults and children have demonstrated that antiretroviral therapy in symptomatic patients slows clinical and immunologic disease progression and reduces mortality (59, 68, 69).

Asymptomatic HIV-Infected Children Under Age 12 Months

Ideally, antiretroviral therapy should be initiated in all HIV-infected infants aged <12 months as soon as a confirmed diagnosis is established — regardless of clinical or immunologic status or viral load. HIV-infected infants aged <12 months are considered at high risk for disease progression, and the predictive value of immunologic and virologic parameters to identify infants who will have rapid progression is less than that for older children. Identification of infection during the first few months of life permits clinicians to initiate antiretroviral therapy or intensify ongoing antiretroviral therapy used for chemoprophylaxis of perinatal transmission during the initial phases of primary infection.

However, **definitive** clinical trial data documenting therapeutic benefit from this approach are not currently available. **Additionally, information on drug dosing in infants under age 3-6 months is limited.** Hepatic and renal functions are immature in the newborn, undergoing rapid maturational changes during the first few months of life. This can result in substantial differences in antiretroviral dose requirements between young infants and older children; for example, data from clinical trials indicate that higher nelfinavir and ritonavir doses are required in infants to achieve therapeutic drug levels (64, 70). Because resistance to antiretroviral drugs (particularly protease inhibitors) can develop rapidly when drug concentrations fall below therapeutic levels (either as a result of inadequate dosage or incomplete adherence), issues associated with adherence should be fully assessed and discussed with the HIV-infected infant's caregivers before the decision to initiate therapy is made.

Asymptomatic HIV-Infected Children Age 12 Months or Older

Two general approaches for initiating therapy in asymptomatic children aged ≥ 1 year were outlined by the Working Group. The first approach would be to initiate therapy in all HIV-infected children, regardless of age or symptom status. Such an approach would ensure: a) treatment of infected children as early as possible in the course of disease and b) intervention before immunologic deterioration. Data from prospective cohort studies indicate that most HIV-infected infants will have clinical symptoms of infection by age one year (71, 72). Most asymptomatic infected children aged >1 year also have CD4⁺ T cell percentages of $<25\%$ (72), which is indicative of immunosuppression (Table 1) and warrants antiretroviral therapy.

An alternative approach would be to defer treatment in asymptomatic children aged ≥ 1 year with normal immune status in situations in which the risk for clinical disease progression is low (i.e., low viral load) and when other factors (i.e., concern for adherence, safety, and persistence of antiretroviral response) favor postponing treatment. In such cases, the health-care provider should regularly monitor virologic, immunologic, and clinical status. Factors to be considered in deciding when to initiate therapy include a) high or increasing HIV RNA levels, b) rapidly declining CD4⁺ T cell count or percentage to values approaching those indicative of moderate immune suppression (i.e., immune category 2 [Table 1]), or c) development of clinical symptoms.

The level of HIV RNA considered indicative of increased risk for disease progression is not well defined for young children. Regardless of age, any child with HIV RNA levels of $>100,000$ copies/mL is at high risk for mortality (Table 4), and antiretroviral therapy should be initiated --- regardless of clinical or immune status. **In older children (≥ 30 months), the risk of disease progression or death at two years of follow-up is very low when HIV RNA levels are $\leq 15,000$ copies/mL, but the risk increases to 13% or higher above that level (Table 6) (39).** Additionally, any child with an HIV RNA level that increases substantially (more than a 0.7 log₁₀ [five fold] increase for children aged <2 years and more than 0.5 log₁₀ [three fold] increase for those aged ≥ 2 years) on repeated testing should be offered therapy regardless of clinical or immunologic status or absolute level of viral load. **This assumes that an alternative cause that could result in a transient elevation in HIV RNA level, such as concurrent immunization or infection, has been ruled out.**

Current recommendations for starting therapy in asymptomatic HIV-infected adults and adolescents are based on both CD4⁺ T cell count and HIV RNA copy number (<http://www.hivatis.org/trtgdlns.html#Adult>) (5). Treatment is recommended for any infected

adult with CD4⁺ T cell count <200/mm³ and should generally be offered for those with CD4⁺ T cell counts between 200 and 350/mm³, regardless of HIV RNA copy number. Some experts would recommend initiating treatment for infected asymptomatic adults with CD4⁺ cell count >350/mm³ if HIV RNA is >30,000 copies/mL using the branched chain DNA assay for HIV RNA or >55,000 copies/ml using the Roche polymerase chain reaction assay.

Issues associated with adherence to treatment are especially important in considering whether and when to initiate therapy. Antiretroviral therapy is most effective in patients who have never received therapy and who therefore are less likely to have antiretroviral-resistant viral strains. Lack of adherence to prescribed regimens and subtherapeutic levels of antiretroviral medications, particularly PIs, may enhance the development of drug resistance. Participation by the caregivers and child in the decision-making process is crucial, especially in situations for which definitive data concerning efficacy are not available.

Choice of Initial Antiretroviral Therapy

Based on clinical, immunological and virological data from clinical trials in adults and children, antiretroviral drug regimens are listed as Strongly Recommended, Recommended as an Alternative, Offered in Special Circumstances or Not Recommended.

Combination therapy is recommended for all infants, children, and adolescents who are treated with antiretroviral agents (Table 8). When compared with monotherapy, combination therapy a) slows disease progression and improves survival, b) results in a greater and more sustained virologic and immunologic response, and c) delays development of virus mutations which confer resistance to the drugs being used. Monotherapy with the currently available antiretroviral drugs is no longer recommended to treat HIV infection. Use of ZDV as a single agent is appropriate only when used in infants of indeterminate HIV status during the first 6 weeks of life to prevent perinatal HIV transmission. Infants who are confirmed as being HIV-infected while receiving ZDV chemoprophylaxis should be changed to a recommended standard combination antiretroviral drug regimen (Table 8) or, if immediate treatment is deferred, have single agent ZDV discontinued pending therapeutic decisions.

The initial antiretroviral regimen chosen for infected infants theoretically could be influenced by the antiretroviral regimen their mother may have received during pregnancy. However, data from PACTG protocol 076 indicate that ZDV resistance did not account for most infants who became infected despite maternal ZDV treatment (73, 74), and data from PACTG protocol 185 indicate that duration of prior ZDV therapy in women with advanced HIV disease, many of whom received prolonged ZDV before pregnancy, was not associated with diminished ZDV efficacy for reduction of transmission (75). Data do not suggest that the antiretroviral regimen for infected infants should routinely be chosen on the basis of maternal antiretroviral use. However, continuing to monitor the frequency of perinatal transmission of antiretroviral-resistant HIV isolates is crucial, because maternal therapy with multiple antiretroviral agents is becoming more common and the prevalence of resistant viral strains in the HIV-infected population may increase over time. When antiretroviral drug resistance is known or suspected in the mother of a newly diagnosed infant, resistance testing of the infant's viral isolate may be considered to assist in choice of initial antiretroviral therapy.

Aggressive antiretroviral therapy with at least three drugs is recommended for initial treatment of infected children because it provides the best opportunity to preserve immune function and delay

disease progression. The goal of antiretroviral therapy is to maximally suppress viral replication, preferably to undetectable levels for as long a time as possible, while preserving and/or restoring immune function and minimizing drug toxicity.

Based on clinical trials of infected adults and children, the antiretroviral regimen most Strongly Recommended for initial therapy is a combination of one of the recommended dual NRTI regimens with one of the recommended protease inhibitors (Table 8). Clinical trials involving antiretroviral-naïve children (some as young as 15 days of age) as well as antiretroviral-experienced children provide evidence that this combination may reduce HIV RNA to undetectable levels in a substantial proportion of children (63, 64, 76-78), although somewhat less than that observed with similar treatments in infected adults. An analysis from a clinical trial of antiretroviral-experienced, protease inhibitor-naïve children (PACTG 338) has demonstrated that therapy with drug combinations that include a protease inhibitor are more effective than therapy with two NRTI antiretroviral drugs in reducing viral load to undetectable levels (60). Additionally, the combination of two NRTI's with a protease inhibitor was significantly more effective than use of a single NRTI and protease inhibitor in reducing viral load to undetectable levels and increasing CD4 lymphocyte percentage after both 24 and 48 weeks of treatment.

A second Strongly Recommended regimen for initial therapy includes efavirenz (Sustiva), a non-nucleoside reverse transcriptase inhibitor. In a pediatric clinical trial, efavirenz in combination with one or two NRTIs and the protease inhibitor nelfinavir reduced viral load to <400 copies/mL in 76% of treated children and to <50 copies/mL in 63%; the regimen was well-tolerated and the virologic response was sustained through 48 weeks (79). However, a disadvantage of initiating antiretroviral treatment with a regimen that contains drugs from all three currently available drug classes is the potential for development of resistance to all three classes if virologic failure occurs, thereby limiting future therapeutic options. In clinical trials in HIV-infected adults, a protease-inhibitor sparing regimen of efavirenz in combination with ZDV and 3TC was associated with an excellent virologic response, with 70% of treated individuals having HIV RNA <400 copies/mL at 48 weeks (80). However, there have been no clinical trials to date of efavirenz as part of a protease inhibitor-sparing regimen in treatment-naïve pediatric patients.

Antiretroviral regimens Recommended as an Alternative for initial therapy include the combination of nevirapine with two NRTIs and the triple nucleoside analogue regimen of abacavir (ABC), ZDV and 3TC. Additional regimens Recommended as an Alternative include 1) the protease inhibitor formulation of lopinavir/ritonavir (Kaletra), in combination with two NRTIs or one NRTI and an NNRTI; 2) soft gel saquinavir in combination with two NRTIs; and 3) indinavir in combination with two NRTIs (Table 8). The first two of these alternative regimens offer protease-inhibitor sparing regimens as a choice for initial treatment. However, while each of these regimens have demonstrated evidence of virologic suppression in some children, experience in this population is limited (i.e. saquinavir or lopinavir/ritonavir), the durability of suppression is not well defined, and the efficacy may not outweigh potential adverse effects, such as drug toxicity (i.e. indinavir or abacavir). Therefore, at this time, these regimens are secondary choices for use as initial therapy.

Antiretroviral regimens recommended for initial therapy only in Special Circumstances include: 1) a combination of two NRTIs; 2) combination of the protease inhibitor amprenavir with ABC; or 3) combination of amprenavir with two NRTIs. These regimens have shown clinical and/or

virologic benefit in children but either have not suppressed viral load to below detectable levels as consistently as the strongly recommended regimens or the durability of suppression in children is not well defined. Additionally, the liquid formulation of amprenavir should not be used in children under age 3 years due to the high content of propylene glycol and vitamin E. Use of a regimen consisting of two NRTIs alone may be considered when the health care provider or guardian/patient has concerns regarding the feasibility of adherence to a more complex drug regimen. It is important to note that drug regimens that do not result in sustained viral suppression may result in the development of viral resistance to the drugs being used and cross-resistance to other drugs within the same drug class.

Antiretroviral regimens that are not recommended for treatment include single drug therapy and certain dual NRTI combinations ([Table 8](#)). These combinations are not recommended either because of pharmacological antagonism or potential overlapping toxicity.

Other drug combinations that demonstrate sustainable viral load suppression and acceptable toxicity and dosing profiles most likely will become available, which will increase treatment options for children in the future. Since antiretroviral therapy will need to be administered for many years, considerations related to the choice of initial antiretroviral regimen should include an understanding of barriers to adherence, with different regimens requiring complex schedules, food requirements, as well as palatability problems and potential limitations in subsequent treatment options should resistance develop.

Available Antiretroviral Drugs

As of February 2001, there were 15 antiretroviral drugs approved for use in HIV-infected adults and adolescents; 11 of these have an approved pediatric treatment indication. These drugs fall into three major classes, NRTIs, NNRTIs and protease inhibitors. Brief information on drug formulation, dosing, and toxicity for the individual drugs can be found in the [Appendix - Characteristics of Available Antiretroviral Drugs](#).

Nucleoside Analogue Reverse Transcriptase Inhibitors

The NRTIs were the first class of antiretroviral drugs that became available for treatment of HIV infection. These drugs include ZDV, ddI, 3TC, d4T, zalcitabine (ddC), and ABC. All except ddC are available in liquid formulations. Additionally, two fixed-dose drug combination preparations are available in solid formulations – a fixed-dose combination of ZDV/3TC (Combivir) and a fixed-dose formulation of ZDV/3TC/ABC (Trizivir). These latter two drug formulations are approved for use in adolescents and adults but are not recommended for use in children less than 12 years old for which the adult dosage may not be appropriate.

Combination NRTI therapy has been shown to produce superior clinical, virologic and immunologic response compared to single drug NRTI therapy (59, 68), and dual NRTI therapy is the backbone of current combination antiretroviral regimens. Dual NRTI combinations studied in children include ZDV and ddI; ZDV and 3TC; d4T and ddI; d4T and 3TC; ZDV and ddC; and ABC in combination with ZDV, 3TC, d4T or ddI (59, 68, 81-84).

A triple NRTI combination, ZDV, 3TC and ABC, has been shown to reduce viral load to <400 copies/mL in 74% of treatment-naïve adults at 48 weeks of therapy, results similar to those of a protease inhibitor-containing regimen (85, 86). However in a study of this regimen in previously

treated children, the combination showed evidence of only modest viral suppression, with only 10% of 102 children maintaining a viral load of < 400 copies/mL at 48 weeks of treatment (87). This triple NRTI regimen spares the initial use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors and can be administered twice a day in children, which may facilitate adherence (84, 88). However, because of the uncertain long-term durability of viral load suppression with a regimen comprised of three drugs of a single class (NRTIs), disappointing results in the treatment of antiretroviral-experienced children, and the potentially life-threatening hypersensitivity syndrome associated with abacavir (89, 90), this drug combination is Recommended as an Alternative for initial therapy (Table 8).

Non-Nucleoside Analogue Reverse Transcriptase Inhibitors

There are currently three non-nucleoside reverse transcriptase inhibitors (NNRTI's) approved for treatment of HIV infection, nevirapine, efavirenz and delavirdine. Nevirapine has a liquid formulation, and is approved for pediatric use in children aged two months or older. The capsule formulation of efavirenz is approved for use in children over three years of age; a liquid formulation is under study and is available through an expanded access program. Delavirdine is only available in a tablet preparation and is not approved for use in children. The NNRTI class of drugs rapidly reduces viral load; however, drug resistance develops quickly after initiation of monotherapy or with combination therapy that does not fully suppress viral replication, and cross-resistance between drugs in this class is common. Sustained suppression of viral load has been observed in some patients who have been treated with regimens combining an NNRTI with two NRTIs or with an NRTI and a protease inhibitor (63, 91-93).

Efavirenz in combination with one or two NRTIs plus nelfinavir has been shown to produce sustained and durable viral suppression in a large proportion of treated children (79). A protease inhibitor-sparing regimen of efavirenz plus two NRTIs has had similar efficacy in infected adults (80). The latter protease-sparing combination offers an alternative to children when issues of adherence or use of protease inhibitors are problematic. There are currently no pharmacokinetic data available on appropriate dosage of efavirenz in children under age three years. A liquid preparation is currently under study and is available by expanded access, but only a capsular formulation is currently commercially available. Efavirenz either in combination with nelfinavir and one or two NRTIs or with two NRTIs alone is a Strongly Recommended regimen for initial treatment of children who can swallow capsules (Table 8).

Combination therapy with nevirapine, ZDV and ddI in a small number of young, antiretroviral therapy-naïve infants was associated with substantial and sustained viral suppression in some of the infants (63, 92). Treatment of therapy-naïve adults with nevirapine plus dual NRTI regimen demonstrated comparable results to triple therapy with the protease inhibitor indinavir (94), although no similar comparative studies have been performed in children. Nevirapine therapy has been associated with the rare occurrence of significant hypersensitivity reactions, including Steven's Johnson syndrome, and rare but potentially life-threatening hepatitis (5, 95, 96). Therefore, nevirapine in combination with two NRTIs is Recommended as an Alternative regimen for initial treatment of antiretroviral-naïve children.

Protease Inhibitors

Protease inhibitors with formulations appropriate for infants and children who cannot swallow pills/capsules include nelfinavir (Viracept), ritonavir (Norvir), amprenavir (Agenerase), and lopinavir/ritonavir (Kaletra). Nelfinavir is available as a powder formulation that can be mixed with water or food while the others are available in liquid formulations. Indinavir (Crixivan) is recommended for consideration for children who can swallow capsules. The hard-gel capsule formulation of saquinavir (Invirase) has limited bioavailability and thus is not recommended for use with two NRTIs. It is primarily being used in adult patients who were initially placed on this formulation and are continuing to receive antiviral benefit. The soft-gel formulation of saquinavir (Fortovase) with enhanced bioavailability has been approved by the Food and Drug Administration (FDA) for treatment of HIV infection in adults, and is currently being evaluated in children (97).

Nelfinavir and ritonavir are considered Strongly Recommended protease inhibitors for use in combination with two NRTIs as initial therapy in infected children (Table 8).

Lopinavir/ritonavir is approved for children over 6 months of age based on data in a limited number of children. However, until greater experience with lopinavir/ritonavir is available, this fixed-dose combination protease inhibitor is Recommended as an Alternative regimen for initial therapy in children, while it is considered a Strongly Recommended protease inhibitor choice in the adolescent/adult antiretroviral guidelines (5). Indinavir and the soft-gel capsule formulation of saquinavir (Fortovase) when used in combination with two NRTIs are also Recommended as an Alternative regimen for initial therapy due to limited experience in children, lack of approved liquid dosage formulations and/or issues of toxicity. Amprenavir in combination with two NRTIs or with ABC is a regimen that may be offered in Special Circumstances in selected pediatric patients as initial antiretroviral therapy and also may have utility in antiretroviral-experienced patients. Amprenavir should not be used in children < 3 years of age because of the lack of data in children in this age group, the paucity of data in children in general, the uncertain impact of extremely high levels of vitamin E found in the liquid formulation (46 IU of vitamin E per ml; the recommended daily dose of vitamin E in children is 10 IU), and the presence of propylene glycol in the oral liquid preparation in a concentration that exceeds WHO standards for use in infants.

Studies of infected adults have indicated that some drugs that inhibit the cytochrome P450 system, including the protease inhibitor ritonavir, can produce substantial increases in the drug levels of other protease inhibitors. Low-dose, non-therapeutic doses of ritonavir when combined with saquinavir and indinavir have been shown to act as a pharmacological “booster” to produce elevated therapeutic plasma concentrations of the second drug. The protease inhibitor combination lopinavir/ritonavir is a preparation that takes advantage of this pharmacokinetic enhancement by using a low dose of ritonavir to produce sustained therapeutic levels of lopinavir.

Combinations of ritonavir with saquinavir, indinavir or nelfinavir in infected adults have shown evidence of virologic suppression when combined with dual NRTIs (98-101). However, these studies have been predominantly conducted among treatment-experienced adults and it is unclear whether dual protease inhibitors offer any substantial benefit over a single protease inhibitor for initial therapy. Studies of dual protease inhibitor combinations in treatment-experienced children are ongoing but complete data not yet available (84, 102, 103). Because the data on the

pharmacokinetics, safety, and efficacy of dual protease inhibitor combinations in children are limited, use of dual protease inhibitors as a component of initial therapy is not recommended (with the exception of lopinavir/ritonavir, which is Recommended as an Alternative regimen for initial therapy), although they may have utility as a component of secondary treatment regimens for children who have failed initial therapy.

Use of Antiretroviral Agonists and New Classes of Antiretroviral Drugs

Hydroxyurea (Hydrea, Bristol-Myers Squibb), a ribonucleotide reductase inhibitor, reduces the cellular pool of endogenous deoxynucleotide triphosphates and may improve the competitive uptake and utilization of nucleoside analogues during reverse transcription of viral DNA, thereby inhibiting HIV DNA synthesis. While hydroxyurea does not have a direct antiretroviral effect, it may have synergistic activity with ddI and/or d4T therapy. Studies of adults receiving hydroxyurea in combination with ddI and/or d4T have demonstrated some improvement in antiviral effect compared to the use of the NRTIs alone, but have also shown lack of improvement in CD4 cell count and possible enhanced risk of adverse side effects, including fatal hepatic and pancreatic toxicity. These findings suggest that hydroxyurea should only be used with caution in the treatment of infected children (104-106). Studies in HIV-infected children are very limited (107), and until further study has been completed regarding its safety and toxicity in infected children it is not recommended for use for initial therapy in children.

New antiretroviral drugs and combinations are being studied in infected adults and children. A new class of antiretroviral agents called fusion inhibitors have been identified that inhibit viral binding or fusion to host target cells; the available drugs in this class must be administered subcutaneously. Two fusion inhibitors are actively undergoing investigation in infected adult patients. Single and chronic-dosing studies of the fusion inhibitor T-20 is currently in phase I/II clinical trials in infected children (108, 109).

Issues Regarding Antiretroviral Dosing in Neonates

Data regarding the appropriate dosing of antiretroviral drugs in neonates are limited; ZDV is the best studied antiretroviral drug in this age group. The recommended ZDV dosage for infants was derived from pharmacokinetics studies performed in full-term infants (110). Because ZDV is primarily cleared through hepatic metabolism (i.e., glucuronidation), which is immature in neonates, the half-life and clearance of ZDV are prolonged in neonates compared with older infants, thus requiring adjustments in dosing. The dosing regimen for full-term neonates is 2 mg/kg orally every six hours or 1.5 mg/kg intravenously every six hours (Table 8).

Premature infants have even greater immaturity in hepatic metabolic function than do full-term infants, and further prolongation in clearance has been documented in very premature infants (i.e., those born before 34 weeks' gestation) (111). Appropriate ZDV dosing for premature infants has not been defined but is being evaluated in a phase I clinical trial of premature infants born before 34 weeks' gestation (i.e., PACTG protocol 331). The dosing regimen being studied in this trial is 1.5 mg/kg orally or intravenously every 12 hours from birth to age two weeks, then increased to 2 mg/kg orally or intravenously every eight hours after two weeks of age.

The safety and pharmacokinetics of 3TC administered alone or in combination with ZDV in pregnant women and administered for one week to their newborns have been evaluated (112, 113). Clearance was prolonged in these infants. Based on data from this study, the dose

recommended for use in newborns (2 mg/kg orally twice daily) is half the dose recommended in older children (4 mg/kg twice daily). No data are available regarding 3TC pharmacokinetics among infants aged two to six weeks, and the exact age at which 3TC clearance begins to approximate that in older children is not known. However, glomerular filtration approximately doubles during the first four weeks of life and secretion capacity of the kidney reaches adult values about 30 weeks of life; based on these data, the dose of 3TC in a phase II study, PACTG protocol 356, is increased to 4 mg/kg twice daily for infected children over four weeks of age.

The safety and pharmacokinetics of ddI administered to pregnant women and their neonates have been evaluated in PACTG protocol 249(114). A single oral dose of 60 mg/m² at 12-24 hours of age and age six weeks was studied in the neonates. The pharmacokinetics of ddI in four neonates were found to be highly variable, and in three of the four neonates, the oral clearance of ddI increased and the terminal half-life decreased from age one day to six weeks; the mean half-life at day one was 135 minutes versus 68 minutes at six weeks. In a multidosing study (PACTG protocol 239) in infected infants, acceptable pharmacokinetics were found with a ddI dose of 50 mg/m² every 12 hours for infants age 90 days or less.

The pharmacokinetics and safety of d4T in pregnant women and neonates is under study in PACTG protocol 332, but data are not yet available. In this study, the pharmacokinetics of d4T are being studied in the neonate administered as a single dose of 1 mg/kg orally at age six and 42 days; if pharmacokinetics are acceptable, multidosing of 1 mg/kg orally every 12 hours will be studied. In a phase II study, PACTG protocol 356, d4T is administered as an oral dose of 0.5 mg/kg twice daily for infants under age 30 days.

Preliminary data are available on the pharmacokinetics of ABC in neonates from PACTG protocol 321(115). A single 2 mg/kg oral ABC dose was administered to neonates under 30 days of age. Clearance was found to be much less than observed in older children and the half-life significantly longer. The 2 mg/kg dose in the neonate yielded ABC concentrations similar to or greater than the concentration in older children at the recommended dose of 8 mg/kg; in the phase II study PACTG protocol 356, ABC dosing for infants over 30 days of age is 8mg/kg twice daily.

NVP administration to HIV-infected pregnant women during labor and as a single dose of 2 mg/kg orally to their newborns at age two to three days has been studied in a phase I trial (116). The half-life of NVP was prolonged in neonates compared with that in older children, indicating that some modification of NVP dosage is required for administration to neonates. The single dose at 48-72 hours in infants born to women who had received NVP during labor maintained NVP concentrations above the desired 100 mg/mL (10 times the IC₅₀) in the infant through seven days of age. This regimen of a single dose NVP during labor and a single dose to the infant age two to three days was subsequently shown in a phase III clinical trial in Uganda to significantly reduce the risk of perinatal transmission (117).

Information on the NVP dose for treatment of infected neonates (as opposed to prophylaxis of transmission) is less studied. The limited single dose 2 mg/kg NVP pharmacokinetic data in the neonate showed that elimination is lower than in older children but comparable to that in adults (116). However, multidose NVP pharmacokinetics have been evaluated in children as young as two months; in the youngest children, clearance was lower than in older children but greater than in adults, suggesting rapid maturation of NVP metabolism during the first two months of life (118). A study of pharmacokinetics of the single NVP dose in 10 infants born to infected

mothers who have received multiple NVP doses (as opposed to a single dose) during pregnancy indicates that a single infant NVP dose of 2 mg/kg orally at age 48-72 hours did not maintain NVP concentrations above the desired 100 mg/ml through age seven days in four of 10 infants, suggesting possible *in utero* induction of NVP metabolic enzymes in the fetal liver and that NVP may need to be given more than once during the first week of life to maintain virucidal levels when the mother has received NVP treatment during pregnancy(119). The NVP dose for infected infants aged 15 days to three months is under study in a phase II clinical trial, PACTG protocol 356. For infants aged 15 to 29 days, the regimen is 5 mg/kg orally once daily for 14 days, followed by 120 mg/m² orally every 12 hours for 14 days, followed by 200 mg/mm² orally every 12 hours.

Although phase I studies of several PIs (i.e., IDV, RTV, NFV, or SQV in combination with ZDV and 3TC) in pregnant HIV-infected women and their infants are ongoing in the United States, only limited data are available at this time regarding drug dosage, safety, and tolerance of any of the PIs in neonates. In PACTG protocol 353, administration of NFV in a dose of 10 mg/kg three times daily to the neonate for the first six weeks of life produced inadequate NFV levels, and a dose of 40 mg/kg twice daily is currently under study(120). In the phase II trial PACTG protocol 356, preliminary data on the pharmacokinetics of NFV given as 30 mg/kg three times daily in infants 15 days or older found this produced inadequate drug levels, and a dose of 55-65 mg/kg twice daily is currently under study in this age group; infants over three months receive a dose of 30 mg/kg three times daily. Data on dosing of the other PIs in neonates is not available at this time.

Changing Antiretroviral Therapy

When to Change Antiretroviral Therapy

The following three reasons warrant a change in antiretroviral therapy: a) failure of the current regimen with evidence of disease progression based on virologic, immunologic, or clinical parameters; b) toxicity or intolerance to the current regimen; and c) new data demonstrating that a drug or regimen is superior to the current regimen (Table 9). When therapy must be changed because of treatment failure or suboptimal response to treatment, clinicians should work with families to assess the possible contribution of adherence problems to the failure of the current regimen. Issues regarding adherence should be addressed to increase the likelihood of a successful outcome when initiating a new therapy. These issues are best addressed before therapy is instituted and need to be reinforced during therapy.

Intensive family education, training in the administration of prescribed medications, and discussion of the importance of adherence to the drug regimen should be completed before initiation of new treatment. In addition, frequent patient visits and intensive follow-up during the initial months after a new antiretroviral regimen is started are needed to support and educate the family and to monitor adherence, tolerance, and virologic response to the new regimen.

Virologic Considerations for Changing Therapy

Information is limited regarding HIV RNA response to antiretroviral therapy in infants and young children. However, the general virologic principles underlying the use of antiretroviral therapy are similar for all HIV-infected persons. Because HIV RNA monitoring is critical for the management of infected children, Working Group members used the available data, and clinical

experience when definitive data were not available, to make the following recommendations. These recommendations may require modification as new information becomes available.

Ideally, antiretroviral therapy should maximally suppress viral replication to below levels capable of being detected with HIV RNA assays — which may not always be achievable in HIV-infected children. Perinatally infected children generally have high HIV RNA levels, and clinical benefit may be observed with decrements in HIV RNA levels that do not result in undetectable levels. However, failure to maximally suppress replication may be associated with increased probability of viral mutations and the emergence of drug resistance. Consideration of the implications of changing regimens and the choice of new drugs should include an acknowledgment of the potential for limiting the patient's future options for potent therapy.

Consensus recommendations have been developed using plasma HIV RNA measurements to guide changes in antiretroviral therapy for HIV-infected adults (5). The recommendations for adults state that health-care providers should consider changing therapy if a) HIV RNA levels drop less than threefold ($0.5 \log_{10}$) after four weeks of therapy and less than tenfold ($1.0 \log_{10}$) after eight weeks of therapy or b) HIV RNA has not decreased to undetectable levels after four to six months of therapy. Because HIV RNA levels in infants who are perinatally infected are high compared with levels observed when therapy is initiated in most infected adults, the initial virologic response of infected infants and young children to initiation of antiretroviral therapy may take longer than observed in adults (i.e., eight to 12 weeks). In addition, suppression of HIV RNA to undetectable levels may be achieved less often than has been reported for infected adults despite potent combination therapy with two NRTIs and a PI. Therefore, virologic indications for changing therapy in infected children differ slightly from those recommended for infected adults. Adult guidelines should be followed for infected adolescents.

Virologic response should be initially assessed four weeks after therapy is initiated. However, the time required to achieve maximal virologic response to therapy may vary depending on the specific baseline HIV RNA value at the time of starting therapy. If baseline HIV RNA levels are high (i.e., $>1,000,000$ copies/mL), virologic response may not be observed until eight to 12 weeks after initiating antiretroviral therapy. However, if baseline HIV RNA levels are more similar to those observed in untreated infected adults (i.e., $<100,000$ copies/mL), initial response should be observed within four weeks following initiation of therapy. After a maximal virologic response is achieved, HIV RNA levels should be measured at least every three months to monitor continued response to therapy. At least two measurements (taken one week apart) should be performed before considering a change in therapy. The following situations may indicate a need for change in therapy in infected children:

- Less than a minimally acceptable virologic response after eight to 12 weeks of therapy. For children receiving antiretroviral therapy with two NRTIs and a PI, such a response is defined as a less than tenfold ($1.0 \log_{10}$) decrease from baseline HIV RNA levels. For children who are receiving less potent antiretroviral therapy (i.e., dual NRTI combinations), an insufficient response is defined as a less than fivefold ($0.7 \log_{10}$) decrease in HIV RNA levels from baseline.
- HIV RNA not suppressed to undetectable levels after four to six months of antiretroviral therapy. However, although suppression of HIV RNA to undetectable levels and maintenance for prolonged periods is desirable, few data among children indicate that such suppression is always achievable. In addition, the number of alternative therapeutic

regimens for children is limited. The initial HIV RNA level of the child at the start of therapy and the level achieved with therapy should be considered when contemplating potential drug changes. For example, an immediate change in therapy may not be warranted if there is a sustained 1.5 to 2.0 log₁₀ fall in HIV RNA copy number, even if RNA remains detectable at low levels.

- Repeated detection of HIV RNA in children who initially had undetectable levels in response to antiretroviral therapy. The presence of repeatedly detectable RNA suggests the development of resistance or problems with adherence or drug bioavailability. More frequent evaluation of HIV RNA levels should be considered if the HIV RNA increase is limited (i.e., if using an HIV RNA assay with a lower limit of detection of 1,000 copies/mL, there is a ≤ 0.7 log₁₀ increase from undetectable to approximately 5,000 copies/mL in an infant aged <2 years). If adherence to therapy has been inconsistent, renewed efforts to educate the caregivers and patient and closer follow-up from members of a multidisciplinary care team may improve adherence.
- A reproducible increase in HIV RNA copy number among children who have had a substantial HIV RNA response but still have low levels of detectable HIV RNA. Such an increase would warrant a change in therapy if, after initiation of the therapeutic regimen, a greater than threefold (>0.5 log₁₀) increase in copy number is observed in children aged ≥ 2 years. Because of the greater biologic variability in RNA in young children, a change in therapy is warranted when a greater than fivefold (>0.7 log₁₀) increase is observed for children aged <2 years.

Immunologic Considerations for Changing Therapy

CD4⁺ T cell count and percentage are independent predictors of disease progression and mortality in HIV-infected children (38, 39). The association of HIV RNA and CD4⁺ T cell percentage with long-term mortality risk in HIV-infected children has been evaluated; for each absolute decline of five percentiles in CD4⁺ T cell percentage at baseline or during follow-up, the mortality risk ratio increased by 1.3 (95% CI=1.2-1.5), independent of the child's HIV RNA level (38). For children with CD4⁺ T cell percentages of <15% (i.e., those in immune category 3), prognosis also was correlated with the degree of depression of CD4⁺ T cell percentage (i.e., life expectancy was less for children with CD4⁺ T cell percentages of <5% compared with children with CD4⁺ T cell percentages of 10%-14%) (Table 3).

Before considering changing antiretroviral therapy because of a decline in CD4⁺ T cell values, a minimum of one repeated measurement of CD4⁺ T cell values should be obtained at least one week after the initial test. The following are immunologic indications that may warrant a change in antiretroviral therapy for HIV-infected children:

- Change in immune classification (Table 1). However, minimal changes in CD4⁺ T cell percentile that may result in a change in immune category (i.e., from 26% to 24% or from 16% to 14%) may not be as concerning as a rapid substantial change in CD4⁺ T cell percentile within the same immune category (i.e., a decrease from 35% to 25%).
- For children with CD4⁺ T cell percentages of <15% (i.e., those in immune category 3), a persistent decline of five percentiles or more in CD4⁺ T cell percentage (i.e., from 15% to 10% or from 10% to 5%).

- A rapid and substantial decrease in absolute CD4⁺ T cell count (i.e., a >30% decline in <6 months).

Clinical Considerations for Changing Therapy

The occurrence of certain clinical events while receiving antiretroviral therapy is evidence of HIV disease progression and/or a poor prognosis for infants and children. The following clinical criteria warrant consideration of a change in antiretroviral therapy:

- Progressive neurodevelopmental deterioration (i.e., persistence or progression of deterioration documented on repeated testing as demonstrated by the presence of two or more of the following findings: impairment in brain growth, decline of cognitive function documented by psychometric testing, or clinical motor dysfunction). In such cases, the new treatment regimen optimally should include at least one antiretroviral drug with substantial central nervous system penetration (i.e., ZDV or NVP, which have cerebrospinal fluid/plasma ratios >0.5).
- Growth failure (i.e., persistent decline in weight-growth velocity despite adequate nutritional support and without other explanation).
- Disease progression (i.e., advancement from one pediatric clinical category to another [Table 2]). Prognosis is poorer as patients progress to more advanced clinical categories (71). However, in patients with stable immunologic and virologic parameters, progression from one clinical category to another (i.e., from clinical category A to category B) may not represent an indication to change therapy. For example, development of new opportunistic infections, particularly in patients who had severe immunosuppression at the time therapy was initiated, may not reflect a failure of antiretroviral therapy but persistence of immunologic dysfunction despite adequate antiviral response. Thus, in patients whose disease progression is not associated with neurologic deterioration or growth failure, virologic and immunologic parameters should be considered when deciding whether to change therapy.

Choice of a New Antiretroviral Regimen

The choice of a new antiretroviral regimen is dictated by the indications that warranted the change in therapy and the limited available alternative antiretroviral agents. Although the efficacy of different combination antiretroviral regimens in children probably can be extrapolated from clinical trial data obtained for adults, data are limited regarding the pharmacokinetics, appropriate dosing, and short- and long-term safety of various combinations in infected children. New regimens should be chosen partly on the basis of the impact of the changes on future treatment options.

The following principles should be followed when choosing a new antiretroviral regimen in children who have received prior treatment.

- When therapy is changed because of toxicity or intolerance, agents with different toxicity and side-effect profiles should be chosen, when possible. Health-care providers should have comprehensive knowledge of the toxicity profile of each agent before selecting a new regimen. In the event of drug intolerance, change of a single drug in a multidrug regimen and, in certain circumstances, dose reduction are permissible options. However,

antiretroviral drugs should only be reduced to the lower end of the therapeutic range for those antiretrovirals for which an effective dosing range is known, and adequacy of antiretroviral activity should be confirmed by the monitoring of HIV RNA levels.

- When changing therapy because of treatment failure ([Table 9](#)), adherence to therapy should be assessed as a potential cause of failure.
- If the patient is adherent to the prescribed drug regimen, assume the development of drug resistance and, if possible, change at least two drugs to new antiretroviral agents. Change in one drug or addition of a drug to a failing regimen is suboptimal. The new regimen should include at least three drugs, if possible. The potential for cross-resistance between antiretroviral drugs should be considered in choosing new drugs.
- When considering changing to a new regimen, all other medications taken by the patient should be reviewed for possible drug interactions.
- A change to a new regimen, especially one containing PIs, must include a discussion of treatment adherence issues between the caregivers of the infected child and the health-care provider. The health-care provider must recognize that certain medications are difficult to take in combination because of exacting and often conflicting requirements with respect to whether they can be taken with food and other antiretrovirals.
- When changing therapy because of disease progression in a patient with advanced disease, the patient's quality of life must be considered.

Detailed information regarding issues associated with specific drug choices for changing a failing regimen and potential cross-resistance between various antiretroviral drugs is available elsewhere (5). Because these issues are similar for all HIV-infected persons (regardless of age) they are not addressed specifically in this document.

Antiretroviral Drug Resistance Testing

It is important to distinguish between the need to change therapy due to drug failure versus drug toxicity or poor compliance. Viral resistance to antiretroviral drugs is important, but not the only reason for treatment failure. The goal of antiretroviral therapy should be to reduce plasma HIV RNA to below detection of the most sensitive assay available (<50 copies/mL). Accomplishing optimal viral suppression will reduce the likelihood that genetic/phenotypic resistance will emerge.

Genotypic assays are available for detecting specific HIV genetic variants (mutations). They are based on amplification procedures and can usually detect mutations in plasma samples with more than 1000 copies/mL of HIV RNA. Expert clinical interpretation is required to determine if genomic variations coincide with changes known to be associated with antiretroviral resistance. A compilation of the most common HIV-1 mutations selected by the three classes of antiretroviral agents is available on the Internet at <http://hiv-web.lanl.gov>.

Phenotypic assays measure the 50% or 90% inhibitory concentrations of a drug against the virus *in vitro*. These assays historically have been cumbersome and time-consuming. However, more rapid assays based on recombinant DNA technology are being developed. Although phenotypic assays provide important information regarding the sensitivity patterns of the dominant virus tested, minor species of resistant viruses may be missed.

HIV resistance assays may prove useful in guiding initial therapy and in changing failing regimens. However, the value of phenotypic or genotypic assays in guiding treatment has not been established in children. Moreover, standardization of such assays will be necessary before guidelines can be established for the incorporation of these assays into clinical care.

Epidemiological surveys are needed to monitor the prevalence of resistant viruses in specific pediatric populations.

Therefore, specific recommendations cannot be made at this time regarding use of resistance assays for directing antiretroviral drug choices in children. However, if resistance testing is performed to determine its contribution to drug failure, these assays should be done while the child is still receiving antiretroviral drugs. In the absence of antiretroviral drug pressure, wild type virus is likely to replace resistant strains and could mask the presence of resistant virus.

It should be noted that the presence of viral resistance to a particular drug suggests that the specific drug(s) is unlikely to be successful in suppressing viral replication. However, the absence of resistance to a drug does not insure that its use will be successful, particularly if that drug or drugs share cross-resistance with drugs previously used. Although initial studies performed in adults suggest that drug-resistance genotyping modestly improves the response to antiretroviral therapy as reflected by a decline in HIV RNA levels below 200 copies/mL (121), there are no long-term data on the impact of such testing. Moreover, no controlled clinical trials, to date, have been performed in children that assess the benefits of genotypic or phenotypic resistance.

MANAGING COMPLICATIONS OF HIV INFECTION

The USPHS and the IDSA jointly developed and recently published guidelines for the prevention of opportunistic infection in both children and adults infected with HIV infection (122). These guidelines are available online at the HIV/AIDS Treatment Information Service website [See the [1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus \(www.hivatis.org\)](http://www.hivatis.org)] In general, adolescents with HIV infection should be managed according to the guidelines for prevention of opportunistic infections in adults.

At the time that the working group developed the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection (MMWR), a document that included an expanded discussion of individual antiretroviral medications and management of complications in pediatric HIV infection was published as a supplement in *Pediatrics*. (9) Information from the *Pediatrics* supplement will be available shortly by linking to the following topics:

1. Treating Complications of HIV Infection

- a. Treatment of Specific Secondary Infections
- b. Management of Other Complications
- c. Childhood Immunizations
- d. Nutrition & HIV Infection
- e. Neuropsychological Complications of HIV Infection
- f. Palliative Care and Pain Management of HIV Infection

CONCLUSION

The Working Group has attempted to provide information specific to the use of antiretroviral drugs in infants, children, and adolescents while not duplicating the information available in antiretroviral recommendations for adults (5). Documents addressing recommendations for adults should be reviewed for basic information regarding disease pathogenesis and drug interactions. Although the general principles of therapy are the same for HIV-infected adults, adolescents, children, and infants, treatment of infection in pediatric patients requires an understanding of the unique aspects of HIV infection in children. Clinical trials of antiretroviral agents in HIV-infected children and the development of drug formulations appropriate for administration to children have often been delayed until after clinical trials in infected adults have been completed and/or the drug has been approved for use among infected adults. However, despite these delays, the paucity of pediatric-specific data cannot further deter the development of rational and reasonable pediatric treatment guidelines while studies in children are being undertaken. To maximize therapeutic options for HIV-infected pediatric patients throughout the course of their infection, drug formularies should facilitate the use of all FDA-approved antiretroviral agents as treatment options for children. Additionally, the conduct of clinical trials to define the pharmacokinetics, safety, and effectiveness in ameliorating the pediatric-specific manifestations of HIV infection of current and new antiretroviral agents is a priority; studies of new drugs should be conducted coincident with or soon after initial studies have been completed

August 8, 2001

in adults. The Working Group will revise these guidelines as new data regarding antiretroviral therapy for infected infants, children, and adolescents become available.

**Table 1. 1994 Revised Human Immunodeficiency Virus Pediatric Classification System:
Immune Categories Based On Age-Specific CD4⁺ T Cell And Percentage***

Immune category	< 12 mos		1- 5 yrs		6-12 yrs	
	No./mm ³	(%)	No./ mm ³	(%)	No./ mm ³	(%)
Category 1: no suppression	≥ 1,500	(≥25%)	≥1,000	(≥25%)	≥500	(≥25 %)
Category 2 : Moderate suppression	750-1,499	(15%-24%)	500-999	(15%-24%)	200-499	(15%-24%)
Category 3: Severe suppression	<750	(<15%)	<500	(<15%)	<200	(<15%)

* Modified from: CDC. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR* 1994; 43 (No. RR-12): p. 1-10.

Table 2. 1994 Revised Human Immunodeficiency Virus Pediatric Classification System: Clinical Categories*

Category N: Not Symptomatic

Children who have no signs or symptoms considered to be the result of HIV infection or who have only **one** of the conditions listed in category A.

Category A: Mildly Symptomatic

Children with **two** or more of the following conditions but none of the conditions listed in categories B and C:

- Lymphadenopathy (≥ 0.5 cm at more than two sites; bilateral = one site)
- Hepatomegaly
- Splenomegaly
- Dermatitis
- Parotitis
- Recurrent or persistent upper respiratory infection, sinusitis, or otitis media

Category B: Moderately Symptomatic

Children who have symptomatic conditions, other than those listed for category A or category C, that are attributed to HIV infection. Examples of conditions in clinical category B include but are not limited to the following:

- Anemia (< 8 gm/dL), neutropenia ($< 1,000/\text{mm}^3$), or thrombocytopenia ($< 100,000/\text{mm}^3$) persisting ≥ 30 days
- Bacterial meningitis, pneumonia, or sepsis (single episode)
- Candidiasis, oropharyngeal (i.e., thrush) persisting for > 2 months in children aged > 6 months
- Cardiomyopathy
- Cytomegalovirus infection with onset before age one month
- Diarrhea, recurrent or chronic
- Hepatitis
- Herpes simplex virus (HSV) stomatitis, recurrent (i.e., more than two episodes within one year)
- HSV bronchitis, pneumonitis, or esophagitis with onset before age one month
- Herpes zoster (i.e., shingles) involving at least two distinct episodes or more than one dermatome
- Leiomyosarcoma
- Lymphoid interstitial pneumonia (LIP) or pulmonary lymphoid hyperplasia complex
- Nephropathy
- Nocardiosis
- Fever lasting > 1 month
- Toxoplasmosis with onset before age one month
- Varicella, disseminated (i.e., complicated chickenpox)

Category C: Severely Symptomatic

Children who have any condition listed in the 1987 surveillance case definition for acquired immunodeficiency syndrome, with the exception of LIP (which is a category B condition).

* Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR*, 1994. 43 (No. RR-12): p. 1-10.

Table 3. Association Of Baseline CD4⁺ T Cell Percentage With Long-Term Risk For Death In Human Immunodeficiency Virus (HIV)-Infected Children^{*}

Baseline	No. Patients [§]	Deaths [†]	
		No.	(%)
< 5%	33	32	(97%)
5% - 9%	29	22	(76%)
10% - 14%	30	13	(43%)
15% - 19%	41	18	(44%)
20% - 24%	52	13	(25%)
25% -29%	49	15	(31%)
30% - 34%	48	5	(10%)
≥ 35%	92	30	(33%)

* Data from the National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial.

† Mean follow-up: 5.1 years

§ Includes 374 patients for whom baseline CD4⁺ T cell percentage data were available.

Source: Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. *J Infect Dis*, 1997. 175: p. 1029-1038.

Table 4. Association Of Baseline Human Immunodeficiency Virus (HIV) RNA Copy Number With Long-Term Risk For Death In HIV-Infected Children *

Baseline (copies/mL) [§]	No. patients [¶]	Deaths [†]	
		No.	(%)
Undetectable (i.e., ≤4,000)	25	6	(24%)
4,001 – 50,000	69	19	(28%)
50,001 – 100,000	33	5	(15%)
100,001 – 500,000	72	29	(40%)
500,001 – 1,000,000	20	8	(40%)
> 1,000,000	35	25	(71%)
Total	254	92	(36%)

* Data from the National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial.

† Mean follow-up: 5.1 years.

§ Tested by NASBA® assay (manufactured by Organon Teknika, Durham, North Carolina) on frozen stored serum.

¶ Mean age: 3.4 years.

Source: Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. *J Infect Dis*, 1997. 175: p. 1029-1038.

Table 5. Association Of Baseline Human Immunodeficiency Virus (HIV) RNA Copy Number And CD4⁺ T Cell Percentage With Long-Term Risk For Death In HIV-Infected Children^{*}

Baseline HIV RNA [§] (copies/mL)/Baseline CD4 ⁺ T cell percentage	No. patients [¶]	Deaths [†]	
		No.	(%)
≤ 100,000			
≥ 15%	103	15	(15%)
< 15%	24	15	(63%)
> 100,000			
≥ 15%	89	32	(36%)
< 15%	36	29	(81%)

^{*} Data from the National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial.

[†] Mean follow-up: 5.1 years.

[§] Tested by NASBA® assay (manufactured by Organon Teknika, Durham, North Carolina) on frozen stored serum.

[¶] Mean age: 3.4 years.

Source: Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. *J Infect Dis*, 1997. 175: p. 1029-1038.

Table 6. Association Of Baseline Human Immunodeficiency Virus (HIV) RNA Quartile By Age At Entry With Risk For Disease Progression Or Death During Study Follow-Up Among HIV-Infected Children Receiving Antiretroviral Treatment*

Age at entry/Baseline HIV RNA quartiles (copies/mL) †	No. patients	Disease progression or death	
		No.	(%)
< 30 months §			
<1,000 – 150,000	79	9	(11%)
150,001 – 500,000	66	13	(20%)
500,001 – 1,700,000	76	29	(38%)
> 1,700,000	81	42	(52%)
≥ 30 months ¶			
<1,000 – 15,000	66	0	(0%)
15,001 – 50,000	54	7	(13%)
50,001 – 150,000	80	13	(16%)
> 150,000	64	22	(34%)

* Data from the Pediatric AIDS Clinical Trial Group protocol 152.

† Tested by NASBA® assay (manufactured by Organon Teknika, Durham, North Carolina) on frozen stored serum.

§ Mean age: 1.1 years.

¶ Mean age: 7.3 years.

Source: Palumbo PE, Raskino C, Fiscus S, et al. Disease progression in HIV-infected infants and children: predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count. *JAMA*, 1998. 279: p. 756-761.

Table 7. Indications For Initiation Of Antiretroviral Therapy In Children With Human Immunodeficiency Virus (HIV) Infection *

- Clinical symptoms associated with HIV infection (i.e., clinical categories A, B, or C [Table 2]).
- Evidence of immune suppression, indicated by CD4⁺ T cell absolute number or percentage (i.e., immune category 2 or 3 [Table 1]).
- Age < 12 months – regardless of clinical, immunologic, or virologic status^{**}.
- For asymptomatic children aged ≥ 1 year with normal immune status, two options can be considered:

Option 1: Initiate therapy – regardless of age or symptom status.

Option 2: Defer treatment in situations in which the risk for clinical disease progression is low and other factors (i.e., concern for the durability of response, safety, and adherence) favor postponing treatment. In such cases, the health-care provider should regularly monitor virologic, immunologic, and clinical status. Factors to be considered in deciding to initiate therapy include the following:

- High or increasing HIV RNA copy number.
- Rapidly declining CD4⁺ T cell number or percentage to values approaching those indicative of moderate immune suppression (i.e., immune category 2 [Table 1]).
- Development of clinical symptoms.

* Indications for initiation of antiretroviral therapy need to address issues of adherence. Post-pubertal adolescents should follow the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents (<http://www.hivatis.org>).

** The Working Group recognizes that clinical trial data documenting therapeutic benefit from this approach are not currently available, and information on pharmacokinetics in infants under age 3-6 months is limited. This recommendation is based on expert opinion. Issues associated with adherence should be fully assessed, discussed, and addressed with the HIV-infected infant's caregivers before the decision to initiate therapy is made.

Table 8. Recommended Antiretroviral Regimens For Initial Therapy For Human Immunodeficiency Virus (HIV) Infection In Children

Strongly Recommended

Clinical trial evidence of clinical benefit and/or sustained suppression of HIV replication in adults and/or children.

- One highly active protease inhibitors (nelfinavir or ritonavir) plus two nucleoside analogue reverse transcriptase inhibitors.
 - Recommended dual NRTI combinations: the most data on use in children are available for the combinations of ZDV and ddI, ZDV and lamivudine (3TC), and stavudine (d4T) and ddI. More limited data are available for the combinations of d4T and 3TC and ZDV and ddC.*
- For children who can swallow capsules: the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva™)** plus two NRTIs, or efavirenz (Sustiva™) plus nelfinavir and one NRTI.

Recommended as an Alternative

Clinical trial evidence of suppression of HIV replication, but 1) durability may be less in adults and/or children than with strongly recommended regimens or may not yet be defined; or 2) evidence of efficacy may not outweigh potential adverse consequences (i.e., toxicity, drug interactions, cost, etc); 3) experience in infants and children is limited.

- NVP and two NRTIs.
- ABC in combination with ZDV and 3TC.
- Lopinavir/ritonavir with two NRTIs or one NRTI and NNRTI†.
- IDV or SQV soft gel capsule with two NRTIs for children who can swallow capsules.

Offered only in Special Circumstances

Clinical trial evidence of either 1) virologic suppression that is less durable than for the Strongly Recommended or Alternative regimens; or 2) data are preliminary or inconclusive for use as initial therapy but may be reasonably offered in special circumstances.

- Two NRTIs.
- APV in combination with two NRTIs or ABC.

Not Recommended

Evidence against use because 1) overlapping toxicity may occur; and/or 2) use may be virologically undesirable.

- Any monotherapy. ¶
- d4T and ZDV
- ddC* and ddI
- ddC* and d4T
- ddC* and 3TC

* ddC is not available commercially in a liquid preparation; although, a liquid formulation is available through a compassionate use program of the manufacturer (Hoffman-La Roche Inc., (<http://www.rocheusa.com>), Nutley, New Jersey). ZDV and ddC is a less preferred choice for use in combination with a PI.

** EFV is currently available only in capsule form, although a liquid formulation is available through an expanded access program of the manufacturer (Dupont Pharmaceutical Company (<http://www.dupontpharma.com>), Wilmington, Delaware). There are currently no data on appropriate dosage of EFV in children under age three years.

† The data presented to the Food and Drug Administration for review during the drug approval process provided significant data on the pharmacokinetics and safety in children receiving lopinavir/ritonavir (Kaletra™) for 24 weeks. The combination of lopinavir/ritonavir with either two NRTIs or one NRTI and an NNRTI may be moved up to the Strongly Recommended category as experience with this drug is gained by US investigators.

¶ Except for ZDV chemoprophylaxis administered to HIV-exposed infants during the first 6 weeks of life to prevent perinatal HIV transmission; if an infant is confirmed as HIV-infected while receiving ZDV prophylaxis, therapy should be changed to a combination antiretroviral drug regimen.

Table 9. Considerations For Changing Antiretroviral Therapy For Human Immunodeficiency Virus (HIV)-Infected Children

<p>Virologic Considerations *</p> <ul style="list-style-type: none"> • Less than a minimally acceptable virologic response after eight to 12 weeks of therapy. For children receiving antiretroviral therapy with two NRTIs and a PI, such a response is defined as a less than tenfold ($1.0 \log_{10}$) decrease from baseline HIV RNA levels. For children who are receiving less potent antiretroviral therapy (i.e., dual NRTI combinations), an insufficient response is defined as a less than fivefold ($0.7 \log_{10}$) decrease in HIV RNA levels from baseline. • HIV RNA not suppressed to undetectable levels after four to six months of antiretroviral therapy. † • Repeated detection of HIV RNA in children who initially responded to antiretroviral therapy with undetectable levels. § • A reproducible increase in HIV RNA copy number among children who have had a substantial HIV RNA response but still have low levels of detectable HIV RNA. Such an increase would warrant change in therapy if, after initiation of the therapeutic regimen, a greater than threefold ($0.5 \log_{10}$) increase in copy number for children aged ≥ 2 years and greater than fivefold ($0.7 \log_{10}$) increase is observed for children aged < 2 years. <p>Immunologic Considerations *</p> <ul style="list-style-type: none"> • Change in immunologic classification (Table 1). ¶ • For children with $CD4^+$ T cell percentages of $< 15\%$ (i.e., those in immune category 3), a persistent decline of five percentiles or more in $CD4^+$ T cell percentage (i.e., from 15% to 10%). • A rapid and substantial decrease in absolute $CD4^+$ T cell count (i.e., $>30\%$ decline in < 6 months). <p>Clinical Considerations</p> <ul style="list-style-type: none"> • Progressive neurodevelopmental deterioration. • Growth failure defined as persistent decline in weight-growth velocity despite adequate nutritional support and without other explanation. • Disease progression defined as advancement from one pediatric clinical category to another (i.e., from clinical category A to clinical category B). **
--

* At least two measurements (taken one week apart) should be performed before considering a change in therapy.

† The initial HIV RNA level of the child at the start of therapy and the level achieved with therapy should be considered when contemplating potential drug changes. For example, an immediate change in therapy may not be warranted if there is a sustained 1.5 to $2.0 \log_{10}$ decrease in HIV RNA copy number, even if RNA remains detectable at low levels.

§ More frequent evaluation of HIV RNA levels should be considered if the HIV RNA increase is limited (i.e., if when using an HIV RNA assay with a lower limit of detection of 1,000 copies/mL, there is a $\leq 0.7 \log_{10}$ increase from undetectable to approximately 5,000 copies/mL in an infant aged < 2 years).

¶ Minimal changes in $CD4^+$ T cell percentile that may result in change in immunologic category (i.e., from 26% to 24%, or 16% to 14%) may not be as concerning as a rapid substantial change in $CD4^+$ percentile within the same immunologic category (i.e., a drop from 35% to 25%).

** In patients with stable immunologic and virologic parameters, progression from one clinical category to another may not represent an indication to change therapy. Thus, in patients whose disease progression is not associated with neurologic deterioration or growth failure, virologic and immunologic considerations are important in deciding whether to change therapy.

Appendix

CHARACTERISTICS OF AVAILABLE ANTIRETROVIRAL DRUGS

Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs)* †

Abacavir (GW 1592U89, ABC, Ziagen™)

Preparations: Pediatric oral solution: 20 mg/mL; Tablets: 300 mg

Tablets in combination with zidovudine and lamivudine: TRIZIVIR- 300 mg zidovudine , 150 mg lamivudine, and 300 mg abacavir.

Dosage

Neonatal dose: Not approved for infants less than three months of age. In infants between one and three months of age, a dose of 8 mg/kg of body weight twice daily is under study.

Pediatric/Adolescent dose: 8 mg/kg of body weight twice daily, maximum dose 300 mg twice daily.

Adult dose: 300 mg twice daily.

Adult dose of TRIZIVIR: 1 tablet twice daily.

Major toxicities

More common: Nausea, vomiting, fever, headache, diarrhea, rash, and anorexia.

Less common (more severe): Approximately 5% of adults and children receiving ABC develop a potentially fatal hypersensitivity reaction. Symptoms include fever, fatigue, malaise, nausea, vomiting, diarrhea, and abdominal pain or respiratory symptoms such as shortness of breath. Physical findings include lymphadenopathy, ulceration of mucous membranes, and maculopapular or urticarial skin rash. The hypersensitivity reaction can occur without a rash. Laboratory abnormalities include elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, and lymphopenia. This reaction generally occurs in the first six weeks of therapy. Patients suspected of having a hypersensitivity reaction should have ABC stopped and not restarted since hypotension and death have occurred upon rechallenge. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported.

Rare: Pancreatitis, increased liver enzymes, elevated blood glucose, elevated triglycerides, and fatigue.

* Information in this appendix is not all inclusive. Complete and detailed prescribing and toxicity information on these drugs is available from the drug companies and should be reviewed by the health-care provider before prescribing these drugs.

† Adolescents in early puberty (Tanner I-II) should be dosed using pediatric schedules, whereas those in late puberty (Tanner Stage V) should be dosed using adult schedules. Youth who are in the midst of their growth spurt (Tanner III females and Tanner IV males) should be closely monitored for medication efficacy and toxicity when choosing adult or pediatric dosing guidelines.

Drug Interactions

- No significant interactions between ABC, ZDV, and 3TC.
- ABC does not inhibit, nor is it metabolized by, hepatic cytochrome P450 enzymes. Thus, it should not cause changes in drug levels or clearance of agents metabolized through these pathways, such as PIs and NNRTIs.
- Ethanol decreases elimination of ABC, resulting in a modest increase in drug exposure.

Special instructions

- Can be given without regard to food.
- Patients and parents must be cautioned about the risk of serious hypersensitivity reaction. A medication guide and warning card should be provided. Patients experiencing a hypersensitivity reaction should be reported to the Abacavir Hypersensitivity Registry (1-800-270-0425).
- Patients should not interrupt therapy without consulting with their physician.

Didanosine (dideoxyinosine, ddI, Videx®)

Preparations: Pediatric powder for oral solution (when reconstituted as solution containing antacid): 10 mg/mL; Chewable tablets with buffers: 25, 50, 100, 150 mg, and 200mg; Buffered powder for oral solution: 100, 167, and 250 mg; Delayed-release capsules (enteric-coated beadlets): VIDEX EC- 125, 200, 250, and 400 mg.

Dosage

Neonatal dose (infants aged <90 days): 50 mg per m² of body surface area every 12 hours.

Pediatric usual dose: In combination with other antiretrovirals: 90 mg per m² of body surface area every 12 hours.

Pediatric dosage range: 90 to 150 mg per m² of body surface area every 12 hours (Note: may need higher dose in patients with central nervous system disease.)

Adolescent/Adult dose: Body weight ≥60 kg: 200 mg twice daily. Body weight <60 kg: 125 mg twice daily. May be administered once daily in adolescents/adults to improve compliance, however, twice daily dosing provides better therapeutic response than once daily dosing.

VIDEX EC: Adolescent/Adult dose: Body weight > 60 kg: 400 mg once daily. Body weight < 60 kg: 250 mg once daily.

Major toxicities

More common: Diarrhea, abdominal pain, nausea, and vomiting.

Less common (more severe): Peripheral neuropathy (dose related), electrolyte abnormalities, and hyperuricemia. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported.

Rare: Pancreatitis (dose related, less common in children than adults), increased liver enzymes, and retinal depigmentation.

Drug interactions

- Possible decrease in absorption of ketoconazole, itraconazole, and dapsone; administer at least two hours before or two hours after ddI.
- Tetracycline and fluoroquinolone antibiotic absorption significantly decreased (chelation of drug by antacid in pediatric powder and tablets); administer two hours before or two hours after ddI.
- Concomitant administration of ddI and DLV may decrease the absorption of these drugs; separate dosing by at least two hours.
- Administration with PIs: IDV should be administered at least one hour before or after ddI on an empty stomach. RTV should be administered at least two hours before or after ddI.

Special instructions

- ddI formulation contains buffering agents or antacids.
- Food decreases absorption; administer ddI on an empty stomach (one hour before or two hours after a meal). Further evaluation in children regarding administration with meals is under study.
- For oral solution: shake well and keep refrigerated; admixture is stable for 30 days.
- When administering chewable tablets, at least two tablets should be administered to ensure adequate buffering capacity (i.e., if the child's dose is 50 mg, administer two 25 mg tablets and not one 50 mg tablet).

Lamivudine (3TC, Epivir®)

Preparations: Solution: 10 mg/mL; Tablets: 150 mg.

Tablets in combination with zidovudine: COMBIVIR- 300 mg zidovudine and 150 mg lamivudine.

Tablets in combination with zidovudine and abacavir: TRIZIVIR- 300 mg zidovudine, 150 mg lamivudine, and 300 mg abacavir.

Dosage

Neonatal dose (infants aged <30 days): 2 mg per kg of body weight twice daily.

Pediatric dose: 4 mg per kg of body weight twice daily.

Adolescent/Adult dose: Body weight \geq 50 kg: 150 mg twice daily. Body weight <50 kg: 2 mg per kg of body weight twice daily.

Adolescent/Adult dose of COMBIVIR: one tablet twice daily.

Adolescent/Adult dose of TRIZIVIR: one tablet twice daily.

Major toxicities

More common: Headache, fatigue, nausea, diarrhea, skin rash, and abdominal pain.

Less common (more severe): Pancreatitis (primarily seen in children with advanced HIV infection receiving multiple other medications), peripheral neuropathy, decreased neutrophil count, and increased liver enzymes. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported.

Drug interactions

- Trimethoprim/sulfamethoxazole (TMP/SMX) increases 3TC blood levels (possibly competes for renal tubular secretion); unknown significance.
- When used with ZDV may prevent emergence of ZDV resistance, and for ZDV-resistant virus, reversion to phenotypic ZDV sensitivity may be observed.

Special instructions

- Can be administered with food.
- For oral solution: store at room temperature.
- Decrease dosage in patients with impaired renal function.

Stavudine (d4T, Zerit®)

Preparations: Solution: 1 mg/mL; Capsules: 15, 20, 30, and 40 mg.

Dosage

Neonatal dose: Under evaluation in Pediatric AIDS Clinical Trial Group protocol 332.

Pediatric dose: 1 mg per kg of body weight every 12 hours (up to weight of 30 kg).

Adolescent/Adult dose: Body weight \geq 60 kg: 40 mg twice daily. Body weight <60 kg: 30 mg twice daily.

Major toxicities

More common: Headache, gastrointestinal disturbances, and skin rashes.

Less common (more severe): Peripheral neuropathy and pancreatitis. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported.

Rare: Increased liver enzymes.

Drug interactions

- Drugs that decrease renal function could decrease clearance.
- Should not be administered in combination with ZDV (poor antiretroviral effect).

Special instructions

- Can be administered with food.
- Need to decrease dose in patients with renal impairment.
- For oral solution: shake well and keep refrigerated; solution stable for 30 days.

Zalcitabine (ddC, HIVID®)

Preparations: Syrup: 0.1 mg/mL (investigational); Tablets: 0.375 and 0.75 mg.

Dosage

Neonatal dose: Unknown

Pediatric usual dose: 0.01 mg per kg of body weight every eight hours.

Adolescent/Adult dose: 0.75 mg three times a day.

Major toxicities

More common: Headache, gastrointestinal disturbances, and malaise.

Less common (more severe): Peripheral neuropathy, pancreatitis, hepatic toxicity, oral ulcers, esophageal ulcers, hematologic toxicity, and skin rashes. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported.

Drug interactions

- Cimetidine, amphotericin, foscarnet, and aminoglycosides may decrease renal clearance of ddC.
- Antacids decrease absorption of ddC.
- Concomitant use with ddI is not recommended because of the increased risk of peripheral neuropathy.
- Intravenous pentamidine increases the risk for pancreatitis; do not use concurrently.

Special instructions

- Administer on an empty stomach (one hour before or two hours after a meal).
- Decrease dosage in patients with impaired renal function.

Zidovudine (ZDV, AZT, Retrovir®)

Preparations: Syrup: 10 mg/mL; Capsules: 100 mg; Tablets: 300 mg; Concentrate for injection/for intravenous infusion: 10 mg/mL.

Tablets in combination with lamivudine: COMBIVIR- 300 mg zidovudine and 150 mg lamivudine.

Tablets in combination with lamivudine and abacavir: TRIZIVIR- 300 mg zidovudine, 150 mg lamivudine, and 300 mg abacavir.

Dosage

Dose for premature infants: (Standard neonatal dose may be excessive in premature infants.) Under study in Pediatric AIDS Clinical Trials Group protocol 331: 1.5 mg per kg of body weight every 12 hours from birth to two weeks of age; then increase to 2 mg per kg of body weight every eight hours after two weeks of age.

Neonatal dose (infants aged <90 days): Oral: 2 mg per kg of body weight every six hours. Intravenous: 1.5 mg per kg of body weight every six hours.

Pediatric usual dose: Oral: 160 mg per m² of body surface area every eight hours.
Intravenous (intermittent infusion): 120 mg per m² of body surface area every six hours.
Intravenous (continuous infusion): 20 mg per m² of body surface area per hour.

Pediatric dosage range: 90 mg per m² of body surface area to 180 mg per m² of body surface area every six to eight hours.

Adolescent/Adult dose: 200 mg three times a day or 300 mg twice daily.

Adolescent/Adult dose of TRIZIVIR: one tablet twice daily.

Major toxicities

More common: Hematologic toxicity, including granulocytopenia and anemia, and headache.

Less common: Myopathy, myositis, and liver toxicity.

Unusual (severe): Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported

Drug interactions

- Increased toxicity may be observed with concomitant administration of the following drugs (therefore, more intensive toxicity monitoring may be warranted): ganciclovir, interferon-alpha, TMP/SMX, acyclovir, and other drugs that can be associated with bone marrow suppression.
- The following drugs may increase ZDV concentrations (and therefore potential toxicity): probenecid, atovaquone, methadone, valproic acid, and fluconazole.
- Decreased renal clearance may be observed with co-administration of cimetidine (may be significant in patients with renal impairment).
- ZDV metabolism may be increased with coadministration of rifampin and rifabutin (clinical significance unknown); clarithromycin may decrease concentrations of ZDV probably by interfering with absorption (preferably administer four hours apart).
- Ribavirin decreases the intracellular phosphorylation of ZDV (conversion to active metabolite).
- Phenytoin concentrations may increase or decrease.
- Should not be administered in combination with d4T (poor antiretroviral effect).

Special instructions

- Can be administered with food (although the manufacturer recommends administration 30 minutes before or one hour after a meal).
- Decrease dosage in patients with severe renal impairment.
- Substantial granulocytopenia or anemia may necessitate interruption of therapy until marrow recovery is observed; use of erythropoietin, filgrastim, or reduced ZDV dosage may be necessary in some patients.
- Reduced dosage may be indicated in patients with substantial hepatic dysfunction.

- Infuse intravenous loading dose or intermittent infusion dose over one hour.
- For intravenous solution: dilute with 5% dextrose injection solution to concentration ≤ 4 mg/mL; refrigerated diluted solution is stable for 24 hours.
- Some experts in pediatric HIV infection use a dose of 180 mg per m^2 of body surface area every 12 hours when using in drug combinations with other antiretroviral compounds, but data on this dosing in children is limited.

Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) * †

Delavirdine (DLV, Rescriptor®)

Preparations: Tablets: 100 mg and 200 mg.

Dosage

Neonatal dose: Unknown.

Pediatric dose: Unknown.

Adolescent/Adult dose: 400 mg three times a day or 600 mg twice daily (investigational).

Major toxicities

More common: Headache, fatigue, gastrointestinal complaints, and rash (may be severe).

Drug interactions

- Metabolized in part by hepatic cytochrome P450 3A (CYP3A). There could potentially be multiple drug interactions. §
- Before administration, the patient's medication profile should be carefully reviewed for potential drug interactions.
- DLV decreases the metabolism of certain drugs, resulting in increased drug levels and potential toxicity. DLV is not recommended for concurrent use with antihistamines (i.e., astemizole or terfenadine), sedative-hypnotics (i.e., alprazolam, midazolam, or triazolam), calcium channel blockers (i.e., nifedipine), ergot alkaloid derivatives, amphetamines, cisapride, or warfarin.

* Information in this appendix is not all-inclusive. Complete and detailed prescribing and toxicity information on these drugs is available from the drug companies and should be reviewed by the health-care provider before prescribing these drugs.

† Adolescents in early puberty (Tanner I-II) should be dosed using pediatric schedules, whereas those in late puberty (Tanner Stage V) should be dosed using adult schedules. Youth who are in the midst of their growth spurt (Tanner III females and Tanner IV males) should be closely monitored for medication efficacy and toxicity when choosing adult or pediatric dosing guidelines.

§ Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for significant interactions, some of which may be life-threatening with multiple drugs. These interactions are outlined in detail in prescribing information available from the drug companies. These interactions will not be reiterated in this document, and the health-care provider should review those documents for detailed information. Before therapy with these drugs is initiated, the patient's medication profile should be carefully reviewed for potential drug interactions.

- DLV clearance is increased, resulting in substantially reduced concentrations of DLV, with concurrent use of rifabutin, rifampin, or anticonvulsants (i.e., phenytoin, carbamazepine, or phenobarbital). Concurrent use is not recommended.
- Absorption of DLV is decreased if given with antacids or histamine₂ receptor antagonists.
- Increased trough concentrations of DLV if given with ketoconazole or fluoxetine; increased levels of both drugs if DLV is given with clarithromycin.
- DLV increases levels of dapsone and quinidine.
- Administration with protease inhibitors: decreases metabolism of SQV and IDV, resulting in a significant increase in SQV and IDV concentrations and a slight decrease in DLV concentrations.

Special instructions

- Can be administered with food.
- Should be taken one hour before or one hour after ddI or antacids.
- The 100 mg tablets can be dissolved in water and the resulting dispersion taken promptly. However, the 200 mg tablets should be taken as intact tablets, because they are not readily dispersed in water.

Efavirenz (DMP-266, EFV, Sustiva™)

Preparations: Capsules: 50, 100, and 200 mg.

Dosage

Neonatal dose: Unknown

Pediatric dose: Administered once daily. Body weight 10 to <15 kg: 200 mg; 15 to <20 kg: 250 mg; 20 to <25 kg: 300 mg; 25 to <32.5 kg: 350 mg; 32.5 to <40 kg: 400 mg; ≥40 kg: 600 mg. There are currently no data available on the appropriate dosage for children under age three years.

Adult/Adolescent dose: 600 mg once daily

Major toxicities

More common: Skin rash; central nervous system (somnolence, insomnia, abnormal dreams, confusion, abnormal thinking, impaired concentration, amnesia, agitation, depersonalization, hallucinations, euphoria), primarily reported in adults; increased aminotransferase levels, teratogenic in primates (use in pregnancy should be avoided and women of childbearing potential should undergo pregnancy testing before initiating therapy).

Drug interactions

- Mixed inducer/inhibitor of cytochrome P450 3A4 enzymes; concentrations of concomitant drugs can be increased or decreased depending on specific enzyme pathway involved.

- Not recommended for concurrent use: antihistamines (i.e., astemizole or terfenadine), sedative-hypnotics (i.e., midazolam or triazolam), cisapride, or ergot alkaloid derivatives.
- Drug interactions requiring careful monitoring if coadministered: warfarin (levels potentially increased or decreased); ethinyl estradiol (levels potentially increased; while of uncertain clinical significance, a reliable method of barrier contraception should be used in addition to oral contraceptives).
- Enzyme inducers such as rifampin, rifabutin, phenobarbital and phenytoin may decrease EFV concentrations; clinical significance is unknown.
- EFV is highly plasma protein bound, and has the potential for drug interactions with other highly proteinbound drugs (i.e., phenobarbital and phenytoin).
- Clarithromycin levels are decreased while the levels of its metabolite are increased; alternatives to clarithromycin, such as azithromycin, should be considered. Other macrolide antibiotics have not been studied in combination with EFV.
- Administration with protease inhibitors: Coadministration decreases levels of SQV (area under the curve [AUC] decreased by 50%) and IDV (AUC decreased by 31%). Coadministration of SQV as a sole PI is not recommended; IDV dose should be increased if given with EFV (for adults, from 800 mg to 1000 mg every eight hours). Coadministration increases levels of both RTV and EFV (AUC increased by 20% for both), and is associated with a higher frequency of adverse clinical and laboratory findings; monitoring of liver enzymes is recommended if coadministered. Coadministration increases levels of NFV (AUC increased by 20%) but no dose adjustment is needed.

Special instructions

- efavirenz can be taken with and without food. The relative bioavailability of EFV was increased by 50% (range 11-126%) following a high fat meal (1070 kcal, 82 grams fat, 62% of calories from fat - this is equivalent to an intake of 8.2 Milky Way candy bars in one sitting). Because there is no information on safety of EFV when given above the recommended dose, administration with a high fat meal should be avoided due to the potential for increased absorption.
- Capsules may be opened and added to liquids or foods, but EFV has a peppery taste; grape jelly has been used to disguise the taste.
- Bedtime dosing is recommended, particularly during the first two to four weeks of therapy, to improve tolerability of central nervous system side effects.

Nevirapine (NVP, Viramune®)

Preparations: Suspension: 10 mg/mL; Tablets: 200 mg.

Dosage

NVP is initiated at a lower dose and increased in a step-wise fashion. This allows induction of cytochrome P450 3A which results in increased clearance of drug. The

occurrence of rash may be diminished by the stepwise increase in dosage. The following suggested incremental increases in dose are given for days on treatment (not age).

Neonatal dose (through age two months): Under study in Pediatrics AIDS Clinical Trial Group protocol 356: 5 mg/kg of body weight or 120 mg/m² of body surface area once daily for 14 days, followed by 120 mg/m² of body surface area every 12 hours for 14 days, followed by 200 mg/m² of body surface area every 12 hours.

Pediatric dose: * 120-200 mg/m² every 12 hours. Note: Initiate therapy with 120 mg/m² (maximum 200 mg) administered once daily for 14 days. Increase to full dose (120-200 mg/m²) administered every 12 hours (maximum 200 mg every 12 hours) if no rash or other untoward effects.

OR

7 mg/kg every 12 hours < eight years of age

4 mg/kg every 12 hours > eight years of age

Note: Initiate therapy with daily dose for 14 days and increase to full dose if no rash or other untoward effects.

Adolescent/Adult dose: 200 mg every 12 hours. Note: Initiate therapy with 200 mg given once daily for the first 14 days. Increase to full dose administered every 12 hours if there is no rash or other untoward effects.

Major toxicities (continuous dosing, not single dose regimens)

More common: (similar to adults) Skin rash (some severe, requiring hospitalization, and life-threatening, including Stevens-Johnson syndrome, toxic epidermal necrolysis), fever, nausea, headache, and abnormal liver function tests.

Less common: Inflammation of the liver (hepatitis), which rarely may lead to severe and life threatening and in some cases fatal liver damage, and very rarely fatal liver failure and granulocytopenia. Hypersensitivity reactions (including, but not limited to, severe rash or rash accompanied by fever, blisters, oral lesions, conjunctivitis, facial edema, muscle or joint aches, general malaise and/or significant hepatic abnormalities).

Drug interactions

- Induces hepatic cytochrome P450 3A (CYP3A); autoinduction of metabolism occurs in two to four weeks with a 1.5fold to twofold increase in clearance. There could potentially be multiple drug interactions. **

* The majority of clinical trials involving infants and children utilized the 120-200 mg/m² dosing regimen. The new FDA approved regimen, which uses mg/kg dosing, is based on pharmacokinetic modeling designed to achieve similar plasma concentrations as dosing of 150 mg/m². NVP clearance is highest during the first two years of life, decreasing gradually after eight to 12 years of age and approaching adult clearance rates. The new dosing regimen accounts for the changes in clearance that occurs after eight years of age. However, the changes in clearance are gradual and the new mg/kg dosing regimen results in an abrupt 43% decrease in dose size when the 8th birthday is reached. Some clinicians may prefer the mg/m² dosing that was utilized in clinical trials.

** Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for significant interactions, with multiple drugs. Some of which may be life-threatening. These interactions are outlined in detail in prescribing information available from the drug companies. These interactions will not be reiterated in this document, and the health-care provider should review those documents for detailed information. Before therapy with these drugs is initiated, the patient's medication profile should be carefully reviewed for potential drug interactions.

- Before administration, the patient's medication profile should be carefully reviewed for potential drug interactions.
- Administration with PIs: IDV and SQV (hard and soft gel formulations) concentrations are decreased significantly (approximately 25%-30%) when administered with NVP. SQV-HGC (Invirase) is not recommended for use in children and is recommended only in combination with RTV in adults. The adult guidelines recommend that IDV doses be increased by 20% when administered in combination with NVP, while recommending standard doses of NFV or RTV in combination with NVP. Data on specific dosing adjustments in pediatric patients for both IDV and NFV are lacking.
- Antifungals: NVP significantly reduces ketoconazole concentrations and these drugs should not be use concomitantly. If indicated, an alternate antifungal agent, such as fluconazole, should be used.
- Rifampin/Rifabutin: Rifampin significantly decreases NVP concentrations. It is not recommended that these drugs be used together. Rifabutin has less of an effect on NVP concentrations.
- Methadone: Patients on methadone maintenance may experience narcotic withdrawal symptoms when NVP is added to their regimen. If withdrawal symptoms occur, methadone doses should be increased and titrated to patient response.
- Anticonvulsants and psychotropics: There are no data on the extent of drug interactions with the anticonvulsants phenobarbital, phenytoin, and carbamazepine. Serum concentrations of these agents should be monitored. Many of the psychotropics are metabolized by similar metabolic pathways as NVP and may interact; patients should be monitored carefully when these medications are used concomitantly.
- Oral contraceptives: NVP may reduce plasma concentrations of oral contraceptives and other hormonal contraceptives. Oral contraceptives should not be the only means of birth control when used in patients on NVP.

Special instructions

- Can be administered with food.
- May be administered concurrently with ddI.
- NVP-associated skin rash usually occurs within the first six weeks of therapy. If rash occurs during the initial 14-day lead-in period, do not increase dose until rash resolves. NVP should be discontinued immediately in patients who develop severe rash or a rash accompanied by constitutional symptoms (i.e., fever, oral lesions, conjunctivitis, or blistering).
- Severe, life-threatening and in some cases fatal, hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis and hepatic failure, has been reported in NVP-treated patients. Increased serum transaminase levels or a history of hepatitis B or C infection prior to starting NVP are associated with higher risk for hepatic adverse events. The majority of cases have occurred during the first 12 weeks of NVP therapy, and frequent and intensive clinical and laboratory monitoring,

including liver function tests, is important during this time period. However, about one third of cases occurred after 12 weeks of treatment, so continued periodic monitoring of liver function tests is needed. In some cases, patients presented with non-specific prodromal signs or symptoms of hepatitis and progressed to hepatic failure; patients with symptoms or signs of hepatitis should have liver function tests performed. Patients should be instructed to contact their HIV specialist if signs or symptoms develop to determine the need for evaluation. NVP should be permanently discontinued and not restarted in patients who develop clinical hepatitis.

- For suspension: Must be shaken well; store at room temperature.

Protease Inhibitors (PIs) ^{* † §}

Amprenavir (APV, AgeneraseTM)

Preparations: Pediatric oral solution: 15mg/mL; Capsules: 50 and 150mg.

Dosage

Neonatal dose: Not recommended in children < 3 years of age.

Pediatric/Adolescent dose (<50kg): For children 4-12 years of age or 13-16 years olds weighing less than 50 kg: Oral Solution: 22.5 mg/kg twice daily hours or 17mg/kg three times daily (maximum daily dose 2,800 mg). Capsules: 20 mg/kg twice daily or 15 mg/kg three times daily (maximum daily dose 2,400 mg).

Adult dose: 1,200 mg (eight 150 mg capsules) bid

Major toxicities

More common: Vomiting, nausea, diarrhea, perioral paresthesias, and rash.

Less common (more severe): Life-threatening rash, including Stevens-Johnson syndrome in 1% of patients.

Rare: Increased cholesterol levels, new onset diabetes mellitus, hyperglycemia, exacerbation of preexisting diabetes mellitus, hemolytic anemia, and spontaneous bleeding in hemophiliacs.

Drug interactions

- APV is a substrate for and inhibitor of the cytochrome P450 isoenzyme CYP3A4. There could potentially be multiple drug interactions.

* Information in this appendix is not all inclusive. Complete and detailed prescribing and toxicity information on these drugs is available from the drug companies and should be reviewed by the health-care provider before prescribing these drugs.

† Adolescents in early puberty (Tanner I-II) should be dosed using pediatric schedules, whereas those in late puberty (Tanner Stage V) should be dosed using adult schedules. Youth who are in the midst of their growth spurt (Tanner III females and Tanner IV males) should be closely monitored for medication efficacy and toxicity when choosing adult or pediatric dosing guidelines.

§ Data in children is limited, and doses may change as more information is obtained about the pharmacokinetics of these drugs in children.

- Before administration, the patient's medication profile should be carefully reviewed for potential drug interactions.
- Coadministering EFV and APV lowers levels of APV 39% (123).
- APV should not be administered concurrently with astemizole, bepridil, cisapride, dihydroergotamine, ergotamine, midazolam, rifampin and triazolam.
- Although no interaction studies have been conducted, serious drug interactions could occur between amiodarone, lidocaine, tricyclic antidepressants, quinidine and warfarin. It is recommended that the concentration of these drugs be monitored when administered concomitantly with APV.
- Rifampin has been found to reduce plasma concentrations of APV (decreased AUC 82%) and should not be used with APV. APV has no significant effect on rifampin plasma levels.
- The AUC of rifabutin is increased by 193% when given in combination with APV. The dose of rifabutin should be reduced by at least half the recommended dose when given in combination with APV.
- Coadministration of APV with sildenafil (Viagra) is likely to result in increased sildenafil concentrations and patients should be advised that they may be at an increased risk for sildenafil-associated adverse events, including hypotension, visual changes, and priapism.
- The FDA approved formulation of APV contains 46 IU vitamin E/ml of oral solution and 109 IU vitamin E-150 mg capsule. The recommended dose of APV results in a dose of 138 IU/kg/day of vitamin E using the oral solution with a maximum dose of 8,587 IU vitamin E per day. Patients receiving the recommended adult dose of APV in capsule form receive 1,744 IU/day of vitamin E. In comparison, the daily recommended dose for vitamin E in children is 10 IU per day and in adults 30 IU per day. Excess ingestion or administration of vitamin E has been associated with creatinuria, decreased platelet aggregation, impaired wound healing, hepatomegaly, prolongation of the Prothrombin Time and the potentiation of vitamin K deficiency coagulopathy. High dose vitamin E may increase the hypoprothrombinemic response to drugs such as warfarin and dicumarol and concurrent use of vitamin E doses >400 IU/day should be avoided in patients taking oral anticoagulants. Patients taking APV should be advised not to take supplemental vitamin E (124-128).
- The liquid formulation of APV contains propylene glycol in a concentration that exceeds WHO standards for use in infants. The serum half-life of propylene glycol in neonates is prolonged at 16.9 hours compared to five hours in adults, due to the immaturity of alcohol dehydrogenase enzyme activity in young infants. High levels of propylene glycol have been associated with hyperosmolarity, lactic acidosis, seizures, and respiratory depression (129).
- The efficacy of hormonal contraceptives may be reduced in patients receiving APV. Alternate or additional methods of birth control should be coadministered if coadministering with hormonal methods of birth control.

- Other medications that are substrates, inhibitors, or inducers of CYP3A4 could also potentially interact with APV. See the product information for Agenerase for complete list of other drugs, which may potentially interact with APV.
- APV is a sulfonamide. The potential for cross sensitivity between drugs in the sulfonamide class and APV is unknown. APV should be used with caution in patients with sulfonamide allergy.

Special instructions

- APV should not be used in children less than **four** years of age because of the lack of data in children < **4** years of age, the paucity of data in children in general, the uncertain impact of extremely high doses of vitamin E, and the propylene glycol content of the oral liquid preparation.
- The oral solution and capsule formulation are not interchangeable on a mg per mg basis. The oral bioavailability of the oral solution is 14% less than that of the capsule.
- APV may be taken with or without food, but should not be given with a high fat meal (i.e., 6.7 Milky Way bars) as there is a 21% decrease in the AUC when APV is administered after a high fat meal of 67 grams of fat compared with the fasting state.
- Patients taking antacids (or ddI) should take APV at least one hour before or after antacid (or ddI) use.

Indinavir (IDV, Crixivan[®])

Preparations: Capsules: 200 and 400 mg.

Dosage

Neonatal dose: Unknown. Due to side effect of hyperbilirubinemia, should not be given to neonates until further information is available.

Pediatric dose: Under study in clinical trials: 500 mg per m² of body surface area every eight hours. **Patients with small body surface areas may require lower doses (300-400 mg/m² every 8 hours).**

Adolescent/Adult dose: 800 mg every eight hours.

Major toxicities

More common: Nausea, abdominal pain, headache, metallic taste, dizziness, and asymptomatic hyperbilirubinemia (10%).

Less common (more severe): Nephrolithiasis (4%) and exacerbation of chronic liver disease.

Rare: Spontaneous bleeding episodes in hemophiliacs, hyperglycemia, ketoacidosis, diabetes, and hemolytic anemia.

Drug interactions

- Cytochrome P450 3A4 (CYP3A4) responsible for metabolism. There could potentially be multiple drug interactions.[¶]

[¶] Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for significant interactions, some of which may be life-threatening, with multiple drugs. These interactions are outlined in detail in

- Before administration, the patient's medication profile should be carefully reviewed for potential drug interactions.
- IDV decreases the metabolism of certain drugs, resulting in increased drug levels and potential toxicity. IDV is not recommended for concurrent use with antihistamines (i.e., astemizole or terfenadine); cisapride; ergot alkaloid derivatives; or sedative-hypnotics (i.e., triazolam or midazolam).
- IDV levels are significantly reduced with concurrent use of rifampin. Concurrent use is not recommended.
- Rifabutin concentrations are increased, therefore a dose reduction of rifabutin to half the usual daily dose is recommended.
- Ketoconazole and itraconazole cause an increase in IDV concentrations (consider reducing adolescent/adult IDV dose to 600 mg every eight hours).
- Coadministration of clarithromycin increases serum concentration of both drugs (dosing modification not needed).
- Coadministration of NVP may decrease IDV serum concentration.
- Administration with other PIs: coadministration with NFV increases concentration of both drugs; coadministration with SQV increases concentration of SQV.

Special instructions

- Administer on an empty stomach one hour before or two hours after a meal (or can take with a light meal).
- Adequate hydration required to minimize risk of nephrolithiasis (at least 48 oz of fluid daily in adult patients).
- If coadministered with ddI, give at least one hour apart on an empty stomach.
- Decrease dose in patients with hepatic insufficiency.
- Capsules are sensitive to moisture and should be stored in original container with desiccant.

Lopinavir/Ritonavir (Kaletra™, ABT 378, LPV/RTV)

Coformulation of lopinavir and ritonavir: RTV acts as a pharmacokinetic enhancer, not as an antiretroviral agent. It does this by inhibiting the metabolism of lopinavir and increasing lopinavir plasma concentrations.

Preparations: Pediatric oral solution: 80 mg lopinavir and 20 mg ritonavir per mL;
Capsules: 133.3 mg lopinavir/33.3 mg RTV.

prescribing information available from the drug companies. These interactions will not be reiterated in this document, and the health-care provider should review those documents for detailed information. Before therapy with these drugs is initiated, the patient's medication profile should be carefully reviewed for potential drug interactions.

Dosage

Neonatal dose: No pharmacokinetic data on dosing children less than six months of age.

- For individuals not receiving concomitant nevirapine or efavirenz:

Pediatric dose

Six months to 12 years of age (without NVP or EFV)	
7 to < 15 kg	12 mg per kg lopinavir/3 mg per kg ritonavir twice daily with food.
15 to 40 kg	10 mg per kg lopinavir/2.5 mg per kg ritonavir twice daily with food.
> 40 kg	400 mg lopinavir/100 mg ritonavir (three capsules or 5 mL) twice daily with food (same as adult dose).

OR

230 mg per m² lopinavir/57.5 mg per m² ritonavir twice daily with food, up to a maximum of 400 mg lopinavir/100 mg RTV.

Adult/Adolescent dose: 400 mg lopinavir/100 mg ritonavir (three capsules or 5 mL) twice daily with food.

- For individuals receiving concomitant ritonavir or EFV (which induce lopinavir metabolism, reduce plasma levels and require increased lopinavir/ritonavir dosing) and/or treatment-experienced patients where reduced susceptibility to lopinavir is suspected (such as those with prior treatment with other PIs):

Pediatric dose:

Six months to 12 years of age (without NVP or EFV)	
7 to < 15 kg	13 mg per kg lopinavir/3.25 mg per kg ritonavir twice daily with food.
15 to 50 kg	11 mg per kg lopinavir/2.75 mg per kg ritonavir twice daily with food.
> 50 kg	533 mg lopinavir/133 mg ritonavir (four capsules or 6.5 mL) twice daily with food (same as adult dose).

OR

300 mg per m² lopinavir/75 mg per m² ritonavir twice daily with food up to a maximum of 533 mg lopinavir/133 mg ritonavir.

Adult/Adolescent dose: 533 mg lopinavir/133 mg ritonavir (four capsules or 6.5 mL) twice daily with food.

Note: Although pediatric clinical trials utilized the mg per m² body surface area dosing, the FDA-approved doses are based on a mg per kg body weight dosage. The 230 mg per m² lopinavir/57.5 mg per m² RTV twice daily regimen without NVP or EFV and the 300 mg per m² lopinavir/75 mg per m² ritonavir twice daily

regimen with concomitant NVP or EFV resulted in lopinavir concentrations similar to those obtained in adults receiving the 400 mg lopinavir/100 mg ritonavir twice daily regimen (without concomitant NVP or EFV). The pediatric trials were done in NNRTI naïve patients and there is little data in heavily pre-treated pediatric patients. In treatment-experienced patients where reduced susceptibility to lopinavir is suspected, higher doses may be required but there is little data to make definitive dosing recommendations at this time.

Major toxicities

More common: Diarrhea, headache, asthenia, and nausea and vomiting. Increase in blood lipids (cholesterol and triglycerides), and rash in patients receiving lopinavir/ritonavir with other antiretroviral drugs.

Rare: Spontaneous bleeding episodes in hemophiliacs, pancreatitis, hyperglycemia, ketoacidosis, diabetes, and hepatitis.

Drug interactions

- Lopinavir/ritonavir is extensively metabolized by hepatic cytochrome P450 3A (CYP3A). There could potentially be multiple drug interactions.*
- Before administration, the patient's medication profile should be carefully reviewed for potential drug interactions.
- Drugs that should not be coadministered with lopinavir/ritonavir include: antiarrhythmics (i.e., flecainide, propafenone); ergot alkaloid derivatives; antihistamines (i.e., astemizole, terfenadine); cisapride; neuroleptics (i.e., pimozide); sedative-hypnotics (i.e., midazolam, triazolam); HMG-COA reductase inhibitors (i.e., lovastatin, simvastatin); rifampin and St. John's wort.
- EFV and NVP induce the metabolism of lopinavir and decrease plasma concentrations. A dose increase of lopinavir/ritonavir is recommended (see dosage section).
- Anticonvulsant drugs including carbamazepine, phenytoin, and phenobarbital increase CYP3A activity, leading to increased clearance and, therefore, lower levels of lopinavir, and should be used with caution.
- Dexamethasone decreases lopinavir serum concentrations. Use with caution.
- Lopinavir/ritonavir increases serum concentrations of some HMG-CoA reductase inhibitors (i.e., atorvastatin, cerivastatin). Pravastatin and fluvastatin are preferred alternative agents.
- Lopinavir/ritonavir increases serum clarithromycin concentration and clarithromycin dose adjustment is recommended in patients with impaired renal function (CrCl 30-60 mL/min decrease clarithromycin dose by 50%; CrCl < 30 mL/min decrease clarithromycin dose by 75%).
- Lopinavir/ritonavir increases rifabutin and rifabutin metabolite concentrations, and dose reduction of rifabutin by at least 75% of the usual dose is recommended.

* Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for significant interactions with multiple drugs, some of which may be life-threatening. These interactions are outlined in detail in prescribing information available from the drug companies. These interactions will not be reiterated in this document, and the health-care provider should review those documents for detailed information. Before therapy with these drugs is initiated, the patient's medication profile should be carefully reviewed for potential drug interactions.

- Lopinavir/ritonavir increases sildenafil (Viagra) serum concentrations. Reduce dose of sildenafil and monitor for toxicity.
- Lopinavir/ritonavir increases serum concentrations of the antiarrhythmics amiodarone, bepridil, lidocaine (systemic) and quinidine. Monitoring of antiarrhythmic serum concentrations is recommended.
- Lopinavir/ritonavir may increase serum concentrations of the immunosuppressant agents cyclosporine, tacrolimus, and rapamycin. Monitor serum concentrations of these agents when coadministered.
- Lopinavir/ritonavir increases serum concentrations of dihydropyridine calcium channel blockers (i.e., felodipine, nifedipine, nicardipine). Clinical monitoring is recommended.
- Lopinavir/ritonavir decreases methadone serum concentrations when coadministered. Patients should be closely monitored for withdrawal symptoms, and methadone dosage should be increased as necessary.
- Lopinavir/ritonavir increases serum concentrations of ketoconazole and itraconazole. High doses of these agents (>200 mg/day) are not recommended.
- Lopinavir/ritonavir decreases atovaquone concentrations. The clinical significance is unknown.
- Ethinyl estradiol levels are reduced by lopinavir/ritonavir, and alternative or additional methods of birth control should be used if coadministered with hormonal methods of birth control.
- Administration with other PIs: appropriate doses of lopinavir/ritonavir with APV, SQV, IDV, or additional RTV have not been established.
- Lopinavir/ritonavir oral solution contains 42.4% alcohol and can cause a disulfiram-like reaction when coadministered with disulfiram or metronidazole.

Special instructions

- Administer with food. High fat meal increases absorption, especially of the liquid preparation.
- If coadministered with ddI, ddI should be given one hour before or two hours after lopinavir/ritonavir.
- Oral solution and capsules should be refrigerated. Can be kept at room temperature up to 77°F (25°C) if used within two months.

Nelfinavir (NFV, Viracept®)

Preparations: Powder for oral suspension: 50 mg per one level gram scoop full (200 mg per one level teaspoon); Tablets: 250 mg tablet.

Dosage

Neonatal dose: Under study in Pediatric AIDS Clinical Trials Group protocol 353: 40 mg per kg of body weight every 12 hours.

Pediatric dose: Currently under review: 20 to 30 mg per kg of body weight three times a day is the FDA approved dose. However, doses as high as 45 mg/kg every 8 hours are routinely used. Twice daily dosing in pediatric patients is under study (50-55 mg/kg/dose) in older children (>6 years of age).

Adolescent/Adult dose: 1250 mg (5 tablets) twice daily or 750 mg (3 tablets) three times daily. Doses of 1500 mg (6 tablets) twice daily are under study in adults.

Major toxicities

More common: Diarrhea.

Less common: Asthenia, abdominal pain, rash, and exacerbation of chronic liver disease.

Rare: Spontaneous bleeding episodes in hemophiliacs, hyperglycemia, ketoacidosis, and diabetes.

Drug interactions

- NFV is in part metabolized by cytochrome P450 3A4 (CYP3A4). There could potentially be multiple drug interactions.*
- Before administration, the patient's medication profile should be carefully reviewed for potential drug interactions.
- NFV decreases the metabolism of certain drugs, resulting in increased drug levels and potential toxicity. NFV is not recommended for concurrent use with antihistamines (i.e., astemizole or terfenadine); cisapride; ergot alkaloid derivatives; certain cardiac drugs (i.e., quinidine or amiodarone); or sedative-hypnotics (i.e., triazolam or midazolam).
- NFV levels are greatly reduced with concurrent use of rifampin. Concurrent use is not recommended.
- Rifabutin causes less decline in NFV concentrations; if coadministered with NFV, rifabutin should be reduced to one half the usual dose.
- Estradiol levels are reduced by NFV, and alternative or additional methods of birth control should be used if coadministering with hormonal methods of birth control.
- Coadministration with DLV increases NFV concentrations twofold and decreases DLV concentrations by 50%. There are no data on coadministration with NVP, but some experts use higher doses of NFV if used in combination with NVP.
- Administration with other PIs: coadministration with IDV increases concentration of both drugs; coadministration with SQV increases concentration of SQV with little change in NFV concentration; coadministration with RTV increases concentration of NFV without change in RTV concentration.

Special instructions

- Administer with meal or light snack.
- If coadministered with ddI, NFV should be administered two hours before or one hour after ddI.
- For oral solution: powder may be mixed with water, milk, pudding, ice cream, or formula (for up to six hours).

* Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for significant interactions, some of which may be life-threatening, with multiple drugs. These interactions are outlined in detail in prescribing information available from the drug companies. These interactions will not be reiterated in this document, and the health-care provider should review those documents for detailed information. Before therapy with these drugs is initiated, the patient's medication profile should be carefully reviewed for potential drug interactions.

- Do not mix with any acidic food or juice because of resulting poor taste.
- Do not add water to bottles of oral powder; a special scoop is provided with oral powder for measuring purposes.
- Tablets readily dissolve in water and produce a dispersion that can be mixed with milk or chocolate milk; tablets also can be crushed and administered with pudding.

Ritonavir (RTV, Norvir[®])

Preparations: Oral solution: 80 mg/mL; Capsules: 100 mg

Dosage

Neonatal dose: Under study in Pediatric AIDS Clinical Trials Group protocol 354 (single dose pharmacokinetics).

Pediatric usual dose: 400 mg per m² of body surface area every 12 hours. To minimize nausea/vomiting, initiate therapy starting at 250 mg per m² of body surface area every 12 hours and increase stepwise to full dose over five days as tolerated.

Pediatric dosage range: 350 to 400 mg per m² of body surface area every 12 hours.

Adolescent/Adult dose: 600 mg twice daily. To minimize nausea/vomiting, initiate therapy starting at 300 mg twice daily and increase stepwise to full dose over five days as tolerated.

***Pharmacokinetic Enhancer:* Used at lower doses as pharmacokinetic enhancer of other protease inhibitors. Doses most commonly used in adults are 200 mg every 12 hours to 400 mg every 12 hours when combined with other protease inhibitors.**

Major toxicities

More common: Nausea, vomiting, diarrhea, headache, abdominal pain, and anorexia.

Less common: Circumoral paresthesias and increase in liver enzymes.

Rare: Spontaneous bleeding episodes in hemophiliacs, pancreatitis, increased levels of triglycerides and cholesterol, hyperglycemia, ketoacidosis, diabetes, and hepatitis.

Drug interactions

- RTV is extensively metabolized by hepatic cytochrome P450 3A (CYP3A). There could potentially be multiple drug interactions. *
- Before administration, the patient's medication profile should be carefully reviewed for potential drug interactions.
- Not recommended for concurrent use with analgesics (i.e., meperidine, piroxicam, or propoxyphene); antihistamines (i.e., astemizole or terfenadine); certain cardiac drugs (i.e., amiodarone, bepridil hydrochloride, encainide hydrochloride, flecainide acetate,

* Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for significant interactions, some of which may be life-threatening, with multiple drugs. These interactions are outlined in detail in prescribing information available from the drug companies. These interactions will not be reiterated in this document, and the health-care provider should review those documents for detailed information. Before therapy with these drugs is initiated, the patient's medication profile should be carefully reviewed for potential drug interactions.

propafenone, or quinidine); ergot alkaloid derivatives; cisapride; sedative-hypnotics (i.e., alprazolam, clorazepate, diazepam, estazolam, flurazepam, midazolam, triazolam, or zolpidem); certain psychotropic drugs (i.e., bupropion hydrochloride, clozapine, or pimozone); rifampin; or rifabutin.

- Estradiol levels are reduced by RTV, and alternative or additional methods of birth control should be used if coadministering with hormonal methods of birth control.
- RTV increases metabolism of theophylline (levels should be monitored, and dose may need to be increased).
- RTV increases levels of clarithromycin (dose adjustment may be necessary in patients with impaired renal function); desipramine (dose adjustment may be necessary); and warfarin (monitoring of anticoagulant effect is necessary).
- RTV may increase or decrease digoxin levels (monitoring of levels is recommended).
- Drugs that increase CYP3A activity can lead to increased clearance and, therefore, lower levels of RTV include carbamazepine, dexamethasone, phenobarbital, and phenytoin (anticonvulsant levels should be monitored because RTV can affect the metabolism of these drugs as well).
- Administration with other PIs: coadministration with SQV and NFV increases concentration of these drugs with little change in RTV concentration.

Special instructions

- Administration with food increases absorption.
- If RTV is prescribed with ddI, there should be two hours between taking each of the drugs.
- Oral solution must be kept refrigerated and stored in original container; can be kept at room temperature if used within 30 days.
- To minimize nausea, therapy should be initiated at a low dose and increased to full dose over five days as tolerated.
- Techniques to increase tolerance in children: a) mixing oral solution with milk, chocolate milk, or vanilla or chocolate pudding or ice cream; b) dulling the taste buds before administration by chewing ice, giving popsicles or spoonfuls of partially frozen orange or grape juice concentrates; c) coating the mouth by giving peanut butter to eat before the dose; or d) administration of strong-tasting foods such as maple syrup, cheese, or strong-flavored chewing gum immediately after dose.

Saquinavir (SQV, Invirase™ hard gel capsule and Fortovase™ soft gel capsule)

Preparations: Hard gel capsules: 200 mg; Soft gel capsules: 200 mg. **Please note that Saquinavir-HGC (Invirase) is not recommended except in combination with ritonavir.**

Dosage

Neonatal dose: Unknown.

Pediatric dose: Under study: 50 mg per kg body weight every 8 hours as single protease inhibitor therapy. 33 mg per kg body weight every 8 hours as usual therapy with nelfinavir.

Adolescent/Adult dose: Soft gel capsules: 1200 mg three times a day or 1600 mg twice daily.

Major toxicities

More common: Diarrhea, abdominal discomfort, headache, nausea, paresthesias, and skin rash.

Less common: Exacerbation of chronic liver disease.

Rare: Spontaneous bleeding episodes in hemophiliacs, hyperglycemia, ketoacidosis, and diabetes.

Drug interactions

- SQV is metabolized by the cytochrome P450 3A4 (CYP3A4) system in the liver, and there are numerous potential drug interactions.*
- Before administration, the patient's medication profile should be carefully reviewed for potential drug interactions.
- SQV decreases the metabolism of certain drugs, resulting in increased drug levels and potential toxicity. SQV is not recommended for concurrent use with antihistamines (i.e., astemizole or terfenadine); cisapride; ergot alkaloid derivatives, or sedative-hypnotics (i.e., midazolam or triazolam).
- SQV levels are significantly reduced with concurrent use of rifampin (decreases SQV levels by 80%), rifabutin (decreases SQV levels by 40%), and NVP (decreases SQV levels by 25%).
- SQV levels are decreased by carbamazepine, dexamethasone, phenobarbital, and phenytoin.
- SQV levels are increased by DLV and ketoconazole.
- SQV may increase levels of calcium channel blockers, clindamycin, dapsone, and quinidine. If used concurrently, patients should be closely monitored for toxicity.
- Administration with other PIs: coadministration with IDV, RTV, or NFV increases concentration of SQV with little change in concentration of the other drug.

* Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for significant interactions, some of which may be life-threatening, with multiple drugs. These interactions are outlined in detail in prescribing information available from the drug companies. These interactions will not be reiterated in this document, and the health-care provider should review those documents for detailed information. Before therapy with these drugs is initiated, the patient's medication profile should be carefully reviewed for potential drug interactions.

Special instructions

- Administer within two hours of a full meal to increase absorption.
- Concurrent administration of grapefruit juice increases SQV concentration.
- Sun exposure can cause photosensitivity reactions; therefore, sunscreen or protective clothing is recommended.

References

1. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center, Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. *Pediatr Infect Dis*, 1993. 2: p. 513-522.
2. Perelson AS, Neumann AU, Markowitz M, et al., HIV-1 dynamics *in vivo*: virion clearance rate, infected cell life span, and viral generation time. *Science*, 1996. 271: p. 1582-1586.
3. Havlir DV, Richman DD., Viral dynamics of HIV: implications for drug development and therapeutic strategies. *Ann Intern Med*, 1996. 124: p. 984-994.
4. Connor EM, Sperling RS, Gelber R, et al., Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. *N Engl J Med*, 1994. 331: p. 1173-1180.
5. Centers for Disease Control and Prevention, Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. *MMWR*, 1998. 47: p. 43-82 - update April 2001 at <http://www.hivatis.org> (see this website for most updated guidelines).
6. Centers for Disease Control and Prevention, Recommendations of the U.S. Public Health Service Task Force on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. *MMWR*, 1994. 43 (No. RR-11).
7. Centers for Disease Control and Prevention, Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. *MMWR*, 1998. 47((no. RR-2)).
8. Center for Disease Control and Prevention, Guidelines for the use of antiretroviral agents in pediatric HIV infection. *MMWR*, 1998. 47((No. RR-4)): p. 1-38.
9. Working Group on Antiretroviral Therapy and Medical Management of Infants, Children and Adolescents with HIV Infection. Antiretroviral therapy and medical management of Pediatric HIV infection. *Pediatrics*, 1998. 102 (4 supplement): p. 1005-1062.
10. Centers for Disease Control and Prevention, U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. *MMWR*, 1995. 44 (No. RR-7).
11. American Academy of Pediatrics, Committee on Pediatric AIDS, Perinatal human immunodeficiency virus testing. *Pediatrics*, 1995. 95: p. 303-307.
12. American College of Obstetricians and Gynecologists, Human immunodeficiency virus infections in pregnancy. *Int J Gynaecol Obstet*, 1997. 57: p. 73-80.
13. Centers for Disease Control and Prevention, U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs during pregnancy for maternal health and reduction of perinatal transmission of human immunodeficiency virus type 1 in the United States. *MMWR*, 1998. 44 (No. RR-2): p. 1-30.
14. American Academy of Pediatrics, Committee on Pediatric AIDS, Human milk, breastfeeding and transmission of human immunodeficiency virus in the United States. *Pediatrics*, 1995. 96: p. 977-979.
15. Centers for Disease Control and Prevention, 1995 revised guidelines for prophylaxis against *Pneumocystis carinii* pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. *MMWR*, 1995. 44 (No. RR-4).
16. State of New York Department of Health Memorandum No. AI 99-01 "Maternal-Pediatric HIV Prevention and Care Program: HIV counseling and voluntary testing of pregnant women; routine HIV testing of newborns".

17. Dunn DT, Brandt CD, Kirvine A, et al., The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intrauterine and intrapartum transmission. *AIDS*, 1995. 9: p. F7-F11.
18. Steketee RW, Abrams EJ, Thea DM, et al., Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. *J Infect Dis*, 1997. 175: p. 707-711.
19. McIntosh K, Pitt J, Brambilla D, et al., Blood culture in the first 6 months of life for diagnosis of vertically transmitted human immunodeficiency virus infection. *J Infect Dis*, 1994. 170: p. 996-1000.
20. Nesheim S, Lee F, Kalish ML, et al., Diagnosis of perinatal human immunodeficiency virus infection by polymerase chain reaction and p24 antigen detection after immune complex dissociation in an urban community hospital. *J Infect Dis*, 1997. 175: p. 1333-1336.
21. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW., Proposed definitions for *in utero* versus intrapartum transmission of HIV-1. *N Engl J Med*, 1993. 327: p. 1246-1247.
22. Mayaux MJ, Burgard M, Teglas JP, et al., Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. *JAMA*, 1996. 275: p. 606-610.
23. Shearer WT, Quinn TC, LaRussa P, et al., Viral load and disease progression in infants infected with human immunodeficiency virus type 1. *N Engl J Med*, 1997. 336: p. 1337-1342.
24. Kovacs A, Xu J, Rasheed S, et al., Comparison of a rapid non-isotopic polymerase chain reaction assay with four commonly used methods for the early diagnosis of human immunodeficiency virus type 1 infection in neonates and children. *Pediatr Infect Dis J*, 1995. 14: p. 948-954.
25. Comans-Bitter WM, de Groot R, van den Beemd R, et al., Immunophenotyping of blood lymphocytes in childhood: reference values for lymphocyte subpopulations. *J Pediatr*, 1997. 130: p. 388-393.
26. European Collaborative Study, Age-related standards for T lymphocyte subsets based on uninfected children born to human immunodeficiency virus 1-infected women. *Pediatr Infect Dis J*, 1992. 11: p. 1018-1026.
27. Centers for Disease Control and Prevention, 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. *MMWR*, 1994. 43 (No. RR-12): p. 1-10.
28. El-Sadar W, Oleske JM, Agins BD, et al., Evaluation and management of early HIV infection. Clinical Practice Guideline No. 7. (AHCPR Publication No. 94-0572). Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994.
29. Wilfert CM, Gross PA, Kaplan JE, et al., Quality standard for enumeration of CD4+ lymphocytes in infants and children exposed to or infected with human immunodeficiency virus. *Clin Infect Dis*, 1995. 21(Suppl 1): p. S134-S135.
30. Kourtis AP, Ibegbu C, Nahmias AJ, et al., Early progression of disease in HIV-infected infants with thymus dysfunction. *N Engl J Med*, 1996. 335: p. 1431-1436.
31. Katzenstein TL, Pedersen C, Nielson C, et al., Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. *AIDS*, 1996. 10: p. 167-173.
32. Henrard DR, Phillips JF, Muenz LR, et al., Natural history of HIV-1 cell-free viremia. *JAMA*, 1995. 274: p. 554-558.

33. Mellors JW, Kingsley LA, Rinaldo CR, et al., Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. *Ann Intern Med*, 1995. 122: p. 573-579.
34. Clementi M, Menzo S, Bagnarelli P, et al., Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. *Clin Microbiol Rev*, 1996. 9: p. 135-147.
35. Palumbo PE, Kwok SH, Waters S, et al., Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. *J Pediatr*, 1995. 126: p. 592-595.
36. Abrams EJ, Weedon JC, Lambert G, et al., for the NYC Perinatal HIV Transmission Collaborative Study, HIV viral load early in life as a predictor of disease progression in HIV-infected infants (Abstract We.B. 311). Vol 2. 11th International Conference on AIDS, Vancouver, British Columbia, Canada, 1996: p. 25. 1996.
37. McIntosh K, Shevitz A, Zaknun D, et al., Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. *Pediatr Infect Dis J*, 1996. 15: p. 1087-1091.
38. Mofenson LM, Korelitz J, Meyer WA, et al., The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. *J Infect Dis*, 1997. 175: p. 1029-1038.
39. Palumbo PE, Raskino C, Fiscus S, et al., Disease progression in HIV-infected infants and children: predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count. *JAMA*, 1998. 279: p. 756-761.
40. Mellors JW, Munoz A, Giorgi JV, et al., Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med*, 1997. 126: p. 946-954.
41. O'Brien WA, Hartigan PM, Daar ES, et al, for the VA Cooperative Study Group on AIDS., Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. *Ann Intern Med*, 1997. 126: p. 939-945.
42. Hughes MD, Johnson VA, Hirsch MS, et al., Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. *Ann Intern Med*, 1997. 126: p. 929-938.
43. Reichelderfer PS, Coombs RW., Virologic parameters as surrogate markers for clinical outcome in HIV-1 disease: verification, variation, and validation. *J Acquir Immune Defic Syndr*, 1995. 10 (Suppl 2): p. S19-S24.
44. Goetz MB, Moatamed F, Howanitz JH., Measurement of plasma HIV viral load (VL) by bDNA versus RT PCR (PCR) assays. *Clin Infect Dis*, 1997. 25: p. 394. (Abstract 207).
45. Brambilla D, Leung S, Lew J, et al., Interkit differences in plasma HIV-1 RNA levels in mothers enrolled in WITS/ACTG 076. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Washington, DC.,1997. (Abstract 616).
46. Vandamme UM, Schmit JC, Van Dorens S, et al., Quantitation of HIV-1 RNA in plasma; comparable results with NASBA HIV RNA QT and AMPLICOR HIV monitor test. *J Acquir Immune Defic Syndr Hum Retrovirol*, 1996. 13: p. 127-139.
47. Raboud JM, Montaner JSG, Conway B, et al., Variation in plasma RNA levels, CD4 count and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. *J Infect Dis*, 1996. 174: p. 191-194.
48. Grubman S, Gross E, Lerner-Weiss N, et al., Older children and adolescents living with perinatally acquired human immunodeficiency virus. *Pediatrics*, 1995. 95: p. 657-663.

49. Schneider MB, Physical examination. In: Friedman SB, Fisher MM, Schoenberg SK, Alderman EM (eds). *Comprehensive adolescent health care*. 2nd ed. St. Louis, MO: Mosby-Year Book, Inc., 1998: p. 69-80.
50. Rogers A (ed), Pharmacokinetics and pharmacodynamics in adolescents. *J Adolesc Health*, 1994. 15: p. 605-678.
51. Reddington C, Cohen J, Baldillo A, et al., Adherence to medication regimens among children with human immunodeficiency virus infection. *Pediatr Infect Dis J*, 2000. 19: p. 1148-1153.
52. Watson DC, Farley JJ., Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. *Pediatr Infect Dis J*, 1999. 18: p. 682-689.
53. Pizzo PA, Eddy J, Falloon J, et al., Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. *N Engl J Med*, 1988. 319: p. 889-896.
54. McKinney RE, Maha MA, Connor EM, et al., A multicenter trial for oral zidovudine in children with advanced human immunodeficiency virus disease. *N Engl J Med*, 1991. 324: p. 1018-1025.
55. Butler KM, Husson RN, Balis FM, et al., Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. *N Engl J Med*, 1991. 324: p. 137-144.
56. Lewis LL, Venzon D, Church J, et al., Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. *J Infect Dis*, 1996. 174: p. 16-25.
57. Kline MW, Dunkle LM, Church JA, et al., A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. *J Pediatr*, 1995. 96: p. 247-252.
58. Kline MW, Culnane M, Van Dyke RB, et al., A randomized comparative trial of zidovudine (ZDV) versus stavudine (d4T) in children with HIV infection. *Pediatrics*, 1998. 101: p. 214-220.
59. McKinney RE, Johnson GM, Stanley K, et al., A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naïve HIV-1 infection. *J Pediatr*, 1998. 133: p. 500-508.
60. Nachman S, S.K., Yogev R, et al., Nucleoside analogues plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children - a randomized controlled trial. *JAMA*, 2000. 283: p. 492-498.
61. Gortmaker S, Hughes M, Oyomopito R, et al., Impact of introduction of protease inhibitor therapy on reductions in mortality among children and youth infected with HIV-1. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000. Abstract 691.
62. DeMartino M, Tovo P-A, Balducci M, et al., Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. *JAMA*, 2000. 284: p. 190-197.
63. Luzuriaga K, McManus M, Catalina M, et al., Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. *J Virol*, 2000. 74: p. 6984-6991.
64. Chadwick EG, Palumbo P, Rodman J, et al., Early therapy with ritonavir (RTV), ZDV and 3TC in HIV-1-infected children 1-24 months of age. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 2001. Abstract 677.
65. Powderly WG, Saag MS, Chapman S, et al., Predictors of optimal virological response to potent antiretroviral therapy. *AIDS*, 1999. 13: p. 1873-1880.
66. Fessel WJ, Krowka JF, Sheppard HW, et al., Dissociation of immunologic and virologic responses to highly active antiretroviral therapy. *JAIDS*, 2000. 23: p. 314-320.

67. Deeks SG, Wrin T, Liegler T, et al., Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. *N Engl J Med*, 2001. 344: p. 472-480.
68. Englund J, Baker C, Raskino C, et al., Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. *N Engl J Med*, 1997. 336: p. 1704-1712.
69. Katzenstein DA, Hammer SM, Hughes MD, et al., The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. *N Engl J Med*, 1996. 335: p. 1091-1098.
70. Capparelli E, Sullivan J, Mofenson L, et al., Pharmacokinetics (PK) of nelfinavir and its metabolite (M8) in HIV-infected infants following BID or TID administration. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 2001. Abstract 729.
71. Barnhart HX, Caldwell MB, Thomas P, et al., Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. *Pediatrics*, 1996. 97: p. 710-716.
72. Blanche S, Newell ML, Mayaux MJ, et al., Morbidity and mortality in European children vertically infected by HIV-1: the French Pediatric HIV Infection Study Group and European Collaborative Study. *J Acquir Immune Defic Syndr Hum Retrovirol*, 1997. 14: p. 442-450.
73. Eastman PS, Shapiro DE, Coombs RW, et al., Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. *J Infect Dis*, 1998. 177: p. 557-564.
74. McSherry GD, Shapiro DE, Coombs RW, et al., The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type 1 (Pediatric AIDS Clinical Trials Group Protocol 076). *J Pediatr*, 1999. 134: p. 717-724.
75. Stiehm ER, L.J., Mofenson LM, et al., Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. *J Infect Dis*, 1999. 179: p. 567-575.
76. Mueller BU, Nelson RP Jr, Sleasman J, et al., A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. *Pediatrics*, 1998. 101: p. 335-343.
77. Krogstad P, W.A., Luzuriaga K, et al., Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. *Clin Infect Dis*, 1999. 28: p. 1109-1118.
78. Van Rossum AMC, Niesters HGM, Geelen SPM, et al., Clinical and virologic response to combination treatment with indinavir, zidovudine and lamivudine in children with human immunodeficiency virus type-1 infection: a multicenter study in the Netherlands. *J Pediatr* 2000. 136: p. 780-788.
79. Starr SE, F.C., Spector SA, et al., Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. *N Engl J Med*, 1999. 341: p. 1874-1881.
80. Staszewski S, Morales-Ramirez J, Tashima K, et al., Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. *N Engl J Med*, 1999. 341: p. 1865-1873.

81. Kline MW, Van Dyke RB, Lindsey J, et al., Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. *Pediatrics*, 1999. 103: p. (URL: <http://www.pediatrics.org/cgi/content/full/103/5/e62>).
82. Bakshi S, Britto P, Capparelli E, et al., Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine (ddC) and zidovudine (ZDV) in stable, ZDV-treated, pediatric patients with HIV infection. *J Infect Dis*, 1997. 175: p. 1039-1050.
83. Gibb D, Giaquinto C, Debre M, et al., A randomised trial evaluating reverse transcriptase inhibitor (NRTI) regimens with and without nelfinavir (NFV) in HIV-infected children - preliminary results from the PENTA 5 trial. 13th International Conference on AIDS. Durban, South Africa, 2000. Abstract TuPeB3246.
84. Kline MW, Blanchard S, Fletcher CV, et al., A phase I study of abacavir alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. *Pediatrics* 1999;103 (URL <http://www.pediatrics.org/cgi/content/full/103/4/e47>).
85. Fischl M, Greenberg S, Clumeck N, et al., Safety and activity of abacavir (ABC, 1592) with 3TC/ZDV in antiretroviral naïve subjects. 12th World AIDS Conference, Geneva, 1998. (Abstract 127/12230).
86. Fischl M, Greenberg S, Clumeck N, et al., Ziagen combined with 3TC and ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naïve subjects. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 1999. (Abstract 19).
87. Saez-Llorens X, Nelson RP, Emmanuel P, et al., A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. *Pediatrics* 2001;107 (URL <http://www.pediatrics.org/cgi/content/full/107/1/e4>).
88. Hughes W, McDowell JA, Shenep J, et al., Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. *Antimicrobial Agents Chemother*, 1999. 43: p. 609-615.
89. Walensky RP, Goldberg HJ, Daily JP., Anaphylaxis after rechallenge with abacavir. *AIDS*, 1999. 13: p. 999-1000.
90. Frissen PHJ, de Vries J, Weigel HM, Brinkman K., Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. *AIDS* 2001;15:289. GlaxoWellcome. Important safety information on hypersensitivity reactions and Ziagen (abacavir sulfate). August 20, 2000.
91. Wiznia A, Stanley K, Krogstad P, et al., Combination nucleoside analogue reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir or ritonavir in stable antiretroviral-experienced HIV-infected children: week 24 results of a randomized controlled trial - PACTG 377. *AIDS Res Human Retroviruses*, 2000. 16: p. 1113-1121.
92. Luzuriaga K, Bryson Y, Krogstad P, et al., Combination treatment with zidovudine, didanosine and nevirapine in infants with human immunodeficiency virus type 1 infection. *N Engl J Med*, 1997. 336: p. 1343-1349.
93. Luzuriaga K, Wu H, McManus M et al., Dynamics of human immunodeficiency virus type 1 replication in vertically-infected infants. *J Virol*, 1999. 73: p. 1343-1349.
94. Squires K, The Atlantic study: a randomized, open-label trial comparing two protease-inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, final 48 week data. 13th International AIDS Conference. Durban, South Africa, 2000. Abstract LbPeB7046.
95. Bartlett J, on behalf of the FTD-302 Study Investigators and the FTC-302 Independent Steering Committee., Severe liver toxicity in patients receiving two nucleoside analogues and a non-

- nucleoside reverse transcriptase inhibitor. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 2001. Abstract 19.
96. Centers for Disease Control and Prevention, Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures - worldwide, 1997-2000. *MMWR*, 2001;. 49: p. 1153-1156.
 97. Kline MW, F.C., Lindwy JC, et al., A randomized trial of combination therapy with saquinavir soft gel capsules (SQV) in HIV-infected children. *8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 4-8, 2001 (Abstract 683)*, 2001.
 98. Raines CP, Flexner C, Sun E, et al., Safety, tolerability and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. *JAIDS*, 2000. 25: p. 322-328.
 99. Katzenstein TL, Kirk O, Pedersen C, et al., The Danish Protease Inhibitor Study: a randomized study comparing the virologic efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection. *J Infect Dis*, 2000. 182: p. 744-750.
 100. Paredes R, Puig T, Arno A, et al., High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. *JADS*, 1999. 22: p. 132-138.
 101. Rockstroh JK, Bergmann F, Wiesel W, et al., Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. *AIDS*, 2000. 14: p. 1181-1185.
 102. Hoffmann F, Notheis G, Wintergerst U, et al., Comparison of ritonavir plus saquinavir- and nelfinavir- plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency virus type 1 infection. *Pediatr Infect Dis J*, 2000. 19: p. 47-51.
 103. Brundage RC, Kline MW, Lindsey J, et al., Pharmacokinetics of saquinavir (SQV) with nelfinavir (NFV) or ritonavir (RTV) in HIV-infected children. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 2001. Abstract 728.
 104. Rutschmann OT, Vernazza PL, Bucher HC, et al., Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. *AIDS*, 2000. 14: p. 2145-2151.
 105. Moore RD, Wong W-ME, Keruly JC, McArthur JC., Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. *AIDS*, 2001. 14: p. 273-278.
 106. Boxwell D, Toerner J., Fatal hepatotoxicity associated with combination hydroxyurea and nucleoside reverse transcriptase inhibitors (NRTIs): cases from the FDA Adverse Event Reporting System (AERS). 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 2001. Abstract 617.
 107. Kline MW, Calles NR, Simon C, et al., Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine. *Pediatr Infect Dis J*, 2000. 19: p. 1083-1086.
 108. Kosel B, Church J, Cunningham C, et al., Pharmacokinetics of selected doses of T-20, a fusion inhibitor, in HIV-1-infected children. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 2001. Abstract 726.
 109. Church J, Cunningham C, Palumbo P, et al., Safety and antiviral activity of chronic subcutaneous administration of T-20 in HIV-1-infected children. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 2001. Abstract 681.
 110. Boucher FD, Modlin JF, Weller S, et al., Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. *J Pediatr*, 1993. 122: p. 1137-1144.

111. Capparelli EV, Mirochnick MH, Dankner WM., Zidovudine pharmacokinetics in premature infants exposed to HIV. *Pediatr Res*, 1996. 39: p. 169A.
112. Johnson MA, Goodwin C, Yuen GJ, et al., The pharmacokinetics of 3TC administered to HIV-1 infected women (pre-partum, during labour and post-partum) and their offspring. Vol 1. 11th International Conference on AIDS, Vancouver, British Columbia, Canada, 1996:249-50. (Abstract Tu.C. 445).
113. Moodley J, Moodley D, Pillay K, et al., Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. *J Infect Dis*, 1998. 178: p. 1327-1333.
114. Wang Y, Livingston E, Patil S, et al., Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS Clinical Trials Group study. *J Infect Dis*, 1999. 180: p. 1536-1541.
115. Johnson GM, Rodman JH, McDowell M, et al., Preliminary analysis of abacavir succinate (ABC) pharmacokinetics in neonates differs from adults and young children. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000. (Abstract 720).
116. Mirochnick M, Sullivan J, Gagnier P, et al., Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. *J Infect Dis*, 1998. 178: p. 368-374.
117. Guay LA, Musoke P, Fleming T, et al., Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. *Lancet*, 1999. 354: p. 795-802.
118. Luzuriaga K, Bryson Y, McSherry G, et al., Pharmacokinetics, safety and activity of nevirapine in human immunodeficiency virus type 1-infected children. *J Infect Dis*, 1996. 174: p. 713-721.
119. Mirochnick M, Siminski S, Fenton T, et al., Pharmacokinetics of nevirapine (NVP) in pregnant women and their infants following in utero exposure. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000. (Abstract 716).
120. Bryson Y, Stek A, Mirochnick M, et al., PACTG 353: a phase I study of safety, pharmacokinetics and antiviral activity of combination nelfinavir, ZDV and 3TC in HIV-infected pregnant women and their infants. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000. (Abstract 715).
121. Durant J, Glevenbergh P, Halfon P, et al., Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. *Lancet*, 1999. 353: p. 2195-2199.
122. Centers for Disease Control and Prevention, 1997 USPHS/IDSA Guidelines for the Prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. *MMWR*, 1997. 46 (No. RR-12): p. 1-46.
123. Piscitelli S, Vogel S, Sadler BM, et al., Effect of Efavirenz (DMP 266) on the pharmacokinetics of 141W94 in HIV-infected patients. In: Abstracts of the 5th Conference of Retroviruses and Opportunistic Infections. Chicago, IL, 1998. (Abstract 346): p. 144.
124. Hilman RW, Tocopherol excess in man: Creatinuria associated with prolonged ingestion. *Am J Clin Nutr*, 1957. 5: p. 597-600.
125. Johnson L, Bowen FW, Abbasi S, et al., Relationship of prolonged pharmacologic serum levels of vitamin E to incidence of sepsis and necrotizing enterocolitis in infants with birth weight 1,500 grams or less. *Pediatrics*, 1985. 75: p. 619-638.
126. Lemons JA, Maisels MJ., Vitamin E: How much is too much. *Pediatrics*, 1985. 76: p. 625-627.

127. Drug Information for the Health Care Professional (USP DI Volume I) 19th Edition. Rockville, MD. The United States Pharmacopeial Convention, Inc. 1999: p. 2973-2975.
128. Suart MJ, Oski FA., Vitamin E and platelet function. *Am J Pediatr Hematol Oncol*, 1979. 1: p. 77-82.
129. American Academy of Pediatrics, "Inactive" ingredients in pharmaceutical products: update (subject review). *Pediatrics*, 1997. 99: p. 268-278.